Hawaii QUEST Integration

1115 Waiver

Quarterly CMS Monitoring Report

Federal Fiscal Year 2023 1st Quarter (DY29 Q1)

Date Submitted: February 27, 2023	Reporting Period:	October 2022 – December 2022
	Federal Fiscal Quarter:	1st Quarter 2023
	State Fiscal Quarter:	2nd Quarter 2023
	Calendar Year Quarter:	4th Quarter 2022
	Demonstration Year:	29th Year (10/1/22 – 9/30/23)
		This reporting period includes the:
		• last month of 1st Q. DY 29; and the
		1st & 2nd months of 2nd Q. DY 29
		when applying a DY of August 1st – July 31st.

Table of Contents

 I 	ntroduction	3
	Operational Updates	
	A. Key Achievements and Challenges Related to the 1115 Waiver	
	1. Managed Care	4
	2. Home and Community Based Services (HCBS) and Personal Care	5
	3. Other	5
E	3. Issues or Complaints Identified by Beneficiaries	6
(C. Audits, Investigations, Lawsuits, or Legal Actions	7

	D. Unusual or Unanticipated Trends	8
	E. Legislative Updates	8
	F. Descriptions of any Public Forums Held	9
	1. Public Forum for Section 1115 Demonstration Project	9
III.	Performance Metrics	11
	A. Impact of the Demonstration	11
	1. Providing Insurance Coverage to Beneficiaries and the Uninsured Population	11
	2. Outcomes of Care, Quality of Care, Cost of Care, and Access to Care	11
	B. Results of Beneficiary Satisfaction Surveys (if conducted)	11
(C. Results of Grievances and Appeals (from Health Plans)	11
IV.	. Budget Neutrality and Financial Reporting Requirements	12
	A. Financial Performance of the Demonstration	12
	B. Updated Budget Neutrality Workbook	12
	C. Quarterly and Annual Expenditures	12
	D. Administrative Costs	12
V.	Evaluation Activities and Interim Findings	12
	A. Progress Summary of Evaluation Activities	12
	1. Key Milestones Accomplished	12
	2. Challenges Encountered and How They Were Addressed	13
	3. Interim Findings (when available)	13
	4. Status of Contracts with Independent Evaluators (if applicable)	13
	5. Status of Institutional Review Board Approval (if applicable)	13
	6. Status of Study Participant Recruitment (if applicable)	13
	7. Result or Impact of the Demonstration Programmatic Area Defined by CMS that is Unique Demonstration Design or Evaluation Hypotheses	
۱/۱	Med-OLIFST Division Contact	14

Attachments

Attachment A: Up-To-Date Budget Neutrality Summary

The Budget Neutrality Summary (worksheet) for the quarter ending 9/30/2022 is attached. The Budget Neutrality Summary for the quarter ending 12/31/2022 will be submitted by the 2/28/2023 deadline.

Attachment B: Budget Neutrality Workbook

The Budget Neutrality Workbook for the quarter ending 9/30/2022 is attached. The Budget Neutrality Workbook for the quarter ending 12/31/2022 will be submitted by the 2/28/2023 deadline.

Attachment C: Schedule C

Schedule C for the quarter ending 12/31/2022 is attached. Schedule C includes a summary of expenditures for the reporting period.

I. Introduction

Hawaii's QUEST Integration (QI) program is a state of Hawaii (State) Department of Human Services (DHS) and Med-QUEST Division (MQD) comprehensive section 1115(a) Demonstration wavier (Demonstration) that expands Medicaid coverage to children and adults originally implemented on August 1, 1994. QUEST Integration uses capitated managed care as a delivery system unless otherwise indicated. Also, QI provides Medicaid State Plan benefits and additional benefits including institutional, and home and community based, long-term services and supports based on medical necessity and clinical criteria, to beneficiaries eligible under the State Plan and to the Demonstration populations.

Med-QUEST Division continues to focus on a comprehensive health care delivery system transformation, called the HOPE Initiative. "HOPE" stands for Hawaii-Medicaid Ohana-Nui Project Expansion. The goal of the initiative is to achieve the Triple Aim of better health, better care, and sustainable costs for our community using a whole person, whole Family and whole community approach to health and well-being. Med-QUEST Division anticipates that the investments in healthy families and healthy communities will translate to improved health and well-being through decreased onset of preventable illnesses, improved early detection and optimal management of conditions, and a continued sustainable growth rate in healthcare spending from reductions in unnecessary care and shifts of care to appropriate settings. Med-QUEST Division also focuses on the integration of behavioral health and health-related social risk factors taking a whole-person health approach.

HOPE Strategies:

- Invest in primary care, prevention, and health promotion
- Improve outcomes for high-need, high-cost individuals
- · Payment reform and financial alignment
- Support community driven initiatives

The current QI contracts are held by five health plans. Those five health plans are AlohaCare, Hawaii Medical Service Association (HMSA), Kaiser Permanente, 'Ohana Health Plan, and UnitedHealthcare Community Plan (collectively, Health Plans). Med-QUEST Division works closely with the Health Plans to facilitate contract implementation and improve healthcare access and services to members.

II. Operational Updates

A. Key Achievements and Challenges Related to the 1115 Waiver

1. Managed Care

Health Plan Reporting

During this quarter, MQD continued to work with the Health Plans to improve report quality and data submission.

Health Plans continued to submit newly designed reports as part of the QI contract. Health Plans have submitted nearly all remaining reports with the last one submitted on 10/31/2022. Embedded in these reports is a framework to consolidate reporting information into specific focus areas and to analyze performance based on Key Performance Indicators (KPIs) which will be reported in the Performance Metrics section of this 1115 quarterly report once data quality is adequate. During 2021, and continuing into 2022, technical assistance sessions have been held with the Health Plans to socialize and implement the new reports, and ensure that health plan staff understand the methodology and purpose of various fields in the reports. Additional strategies for improving data quality have been developed including report templates with built in quality assurance flags that alert Health Plans of inappropriate or mis-formatted data. Report tools for these reports have been updated based on feedback from the Health Plans, and such updates are incorporated into the Health Plan Manual. Med-QUEST Division is looking at ways to streamline reporting and reduce administrative burden on Health Plans and MQD staff. These include combined data files and working toward more automated reporting.

Dual Eligible Special Needs Plans (D-SNPs)

MQD's analyses and discussions of key policies and operational options regarding HIDE-SNPs and FIDE-SNPs, led by consultants, ATI Advisory (ATI) and Speire Healthcare Strategies, LLC (Speire) during last quarter, paid off this quarter. This quarter, having trimmed the focus to select HIDE and FIDE considerations, MQD and its consultants introduced and discussed these with the Hawaii D-SNPs and other MQD staff, for initial feedback and suggestions. These introductions were

initiated during on-site meetings the first week of October 2022, with ATI and Speire representatives on-site.

As a result of the on-site presentation and discussions, Hawaii decided to make FIDE-SNPs optional for its D-SNPs in 2024, and to revisit a single contract pathway in the future. Hawaii also decided its FIDE-SNPs will operate with Exclusively Aligned Enrollment (EAE) beginning in 2024. There was a broad range of other topics covered such as aligned care management, integrated beneficiary materials, default enrollment, data sharing, and unified grievances and appeals.

With feedback and suggestions from the stakeholders and a better understanding of the Health Plan consideration for the discussed requirements, MQD and its consultants are preparing to finalize policy decisions and think through new draft language for the 2024 Hawaii State Medicaid Agency Contract (SMAC).

2. Home and Community Based Services (HCBS) and Personal Care

A rate study for several Home and Community Based Services (HCBS) was completed December 31, 2022. The MQD completed a study of home and community based rates paid for community residential providers such as: Community Care Foster Family Homes (CCFFHs); Expanded—Adult Residential Care Homes (E-ARCHs); In-Home Services; and Case Management Services. The study was done by Milliman, an actuarial firm contracted with DHS MQD for a wide range of actuarial consulting services. The study commenced in July 2022, and the final report issued December 30, 2022.

A key part of this rate study, included stakeholder outreach and engagement with HCBS providers and their associations, collecting provider cost and wage survey data, and getting provider feedback on draft rate calculations. Not surprisingly, the provider surveys showed significant wage pressure given the current labor market. The rate study methodology also used wage and salary data for direct care staff and supervisors, employee related expenses, transportation and administration, program support and overhead, and the Bureau of Labor and Industry Wage Indices to paying for employment benefits such as health insurance.

The rate study provides three scenarios (low, medium, high) based on different wage or caseload/staffing assumptions. A low scenario includes the lowest wage or highest caseload assumptions to calculate the lowest rates. A medium scenario includes middle wage or caseload assumptions, and a high scenario includes the highest wages or lowest caseload assumptions to calculate the highest rates (e.g., adjusting wages would create a low scenario with wage assumptions set at the 25th percentile, a medium scenario with wage assumptions set at the 50th percentile, and a high scenario with wage assumptions set at the 75th percentile). A legislative report incorporated the rate study, so that the legislature could consider budget appropriation based on the results when the legislature began in mid-January 2023.

3. Other

Member Outreach

In this quarter, Health Care Outreach Branch (HCOB) prepared for and conducted our Annual Kokua Training, which included training on how to properly complete a Medicaid application and the application at the healthcare.gov marketplace. We also reviewed the State Funded Premium

Assistance program for those who do not qualify for Medicaid due to their citizenship status. Cultural competency training was also provided in our sessions. All the training efforts are done in preparation for the Med-QUEST Annual Plan Change and the Marketplace Open Enrollment, during which time many individuals may need assistance. Med-QUEST Division's outreach program has grown while it has completed training for, and provided online access to, its Navigator Portal, to approximately 170 Kokua this year. The HCOB continues to do outreach and provide enrollment assistance for the vulnerable and justice involved populations.

Managed Care Annual Plan Change

The Med-QUEST Annual Plan Change took place from October 1st through October 31st of 2022. Plan changes made during this period became effective January 1, 2023. About 1% of QI enrollees chose to change plans. HMSA received the largest number of individuals switching to its plan, followed by United Healthcare, and then Kaiser Permanente. AlohaCare and Ohana Health Plan experienced net losses.

Sum	mary			Gaining	g Plans		
		ALOHA- CARE	HMSA	KAISER	OHANA	UNITED	TOTAL
S	ALOHACARE		1,069	258	44	215	1,586
Plans	HMSA	333		513	79	447	1,372
lg F	KAISER PERMANENTE	62	399		21	93	575
Losing	OHANA HEALTH PLAN	131	667	137		327	1,262
٦	UNITED HEALTH CARE	151	701	157	68		1,077
	Total	677	2,836	1,065	212	1,082	5,872

Data Quality Strategy

Med-QUEST Division continued working toward its 2022 Data Quality Strategy goals with partnered contractor, Freedman Healthcare. In this quarter, contractors identified a set of edits being applied in back-end adjudication of encounters that do not align with MQD's business policies. By turning these edits off, MQD will prevent encounters from unnecessarily pending. This quarter MQD also finalized a new reconciliation process at the file-level that will give MQD and its contractors more insight into where errors are occurring in the MQD mainframe's adjudication processes.

B. Issues or Complaints Identified by Beneficiaries

No reports relevant to the Demonstration to report at this time.

C. Audits, Investigations, Lawsuits, or Legal Actions

Audits and Investigations

Two payment suspensions were issued this quarter for dentists billing for medically unnecessary services.

Audit coordination with the Unified Program Integrity Contractor (UPIC) included:

- 1. Lab billing of presumptive and confirmatory drug screens
- 2. Sleep center and DME billing of CPAP machines
- 3. Podiatry provider various coding and documentation deficiencies.

Lawsuits and Legal Actions

Administrative Hearings:

Ka Punawai Ola v. Med-QUEST. The provider appealed, through the administrative process at DHS, a request for reimbursement of state and federal Medicaid funds received for care of a member in a nursing facility whose residence in the facility was not properly vetted through the Preadmission Screening Resident Review (PASSR) process. The provider settled by agreeing to fully reimburse the federal Medicaid funds and half of the state funds. The provider paid in full on the settlement in December 2022.

Waianae Coast Comprehensive Health Center (WCCHC) v. DHS. WCCHC is a federally qualified health center and receives reimbursement under the Prospective Payment System (PPS) of reimbursement created under Hawaii Revised Statutes §§346-53.62, et seq. In February 2019, WCCHC requested a rate change for its medical PPS and dental PPS rates.

MQD ultimately denied the request for a rate change for the dental PPS rate because the services actually began in 2010 and WCCHC did not provide documentation to support the change in an increased type, intensity, duration, or amount, of services for the 2019 year.

As for the medical PPS rate change request, after extensive discussion, requests for data, and review of their data, MQD issued a projected adjusted medical PPS rate in September 2019. MQD then provided payments on that projected adjusted medical PPS rate, requested data, and reviewed data until a final adjusted PPS rate was determined in November 2020. MQD provided final settlements based on the final medical PPS rate. All required notices were sent by certified mail in compliance with Hawaii Administrative Rules.

Years after these decisions, around October 2022, WCCHC requested an administrative hearing to contest the final settlement for 2019 (notice dated September 10, 2021), final adjusted medical PPS rate (notice dated November 19, 2020), the denial of the request for a dental PPS rate change (notice dated November 19, 2020), and check payments that were provided to WCCHC checks (dated December 18, 2020). MQD moved to dismiss the hearing for failure to timely request an administrative hearing pursuant to Hawaii Administrative Rule (HAR) §§17-1736-58 and 59. These rules required WCCHC to request an administrative hearing 90 days after the decisions were issued and limit its right to a hearing when the request is not timely made. The Hearing Officer granted MQD's motion to dismiss.

Bekkum v. DHS. Curtis Bekkum, M.D. appeals MQD's decision to terminate him based on a criminal complaint and conviction of sexual assault, which occurred in his provision of medical services to a patient. Bekkum moved to delay the administrative proceedings until his appeal to the Intermediate Court of Appeals was complete. MQD submitted arguments in opposition. The Hearing Officer denied Bekkum's motion and set the hearing for April 2023.

9th Circuit Court of Appeals:

HRDC v. Kishimoto. This was a challenge to the State of Hawaii's provision of Medicaid funded Applied Behavioral Analysis (ABA) therapy for children on the autism spectrum attending public schools. The State of Hawaii won a Motion for Summary Judgment in the federal district court on August 31, 2022 and the Plaintiffs appealed to the 9th Circuit Court of Appeals on September 30, 2022. The case remains on appeal to the 9th circuit.

Hawaii Courts:

Nitta v. Med-QUEST. Frederick Nitta is an obstetrics and gynecologist who also provides some primary care services. The ACA provided enhanced payments for primary care services only for physicians who had a primary specialty designation in family, internal, or pediatric medicine. Nitta claimed those enhanced payments and was paid the enhanced payments. After an internal audit revealed that Nitta was not eligible for the program because his primary specialty designation was OB/GYN, Med-QUEST sought to recoup the overpayment of those enhanced payments. Nitta requested an administrative appeal, and the hearing officer agreed with Med-QUEST's action. On appeal, the Circuit Court affirmed the hearing officer's decision. During the appeal to the Intermediate Court of Appeals (ICA), the Sixth Circuit Averett decision was issued. Based on that decision, the ICA voided the Circuit Court decision and remanded the matter back to the DHS Administrative Appeals Office. DHS appealed the ICA decision to the Hawaii Supreme Court and argued that even if the Averett analysis was applied, Nitta is not eligible for the enhanced payments because his primary specialty designation was obstetrics and gynecology. The Hawaii Supreme Court disagreed with DHS and found that a physician can have more than one primary specialty designation. DHS discussed this case with CMS at a meeting around November 15, 2022.

Evergreen v. DHS (Tort). The Complaint alleges that MQD interfered with Provider's ability to secure contracts with the Health Plans and that MQD does not supervise their fraud investigator. The State has not been perfected.

D. Unusual or Unanticipated Trends

No unusual trends at this time other than the continued effects of the pandemic and continuous coverage requirements. There is a 40 percent increase in Medicaid enrollment.

E. Legislative Updates

Hawaii elected a new governor, Governor Josh Green, M.D. He has prioritized increasing reimbursement rates for medical and professional services. Also, a workgroup that included legislators focused on

strengthening Home and Community Based Services, and as a result of the American Rescue Plan Act (ARPA) 9817 funded rate study, a Home and Community Based rate study was completed and included in a legislative report. See section II.A.2 above for more on that rate study.

F. Descriptions of any Public Forums Held

1. Public Forum for Section 1115 Demonstration Project

Hawaii held two Med-QUEST Healthcare Advisory Committee (MHAC) meetings during this reporting period on October 19, 2022, and December 14, 2022. Public comments were received from both meetings and are summarized below.

MHAC meeting, October 19, 2022

Med-QUEST presented information and updates on Adult Dental Services, Annual Plan Change, Home and Community Based Services (HCBS) and the American Rescue Plan (ARP) spending activities for the HCBS Rate Study and the Person-Centered Planning. Med-QUEST Division also presented on State Plan Amendments (SPA) related to Community Palliative Care Services and Monkeypox vaccine administrative rates, and Member Communications related to the Public Health Emergency Unwinding and Renewals and Redeterminations.

Comments and questions were received by both the MHAC members and the public regarding the Adult Dental Services. One member from MHAC wanted to know if there were contracted providers already in place to perform the dental services. Med-QUEST Division confirmed that there are contracted dental providers in place and that MQD is actively seeking additional providers. One member from the public had questions regarding specific rates for FQHCs regarding lab costs and MQD explained this will be addressed on the PPS rate for dental. Another member of the public thanked MQD for providing Adult dental services and inquired when the Hawaii Administrative Rules (HAR) will be issued regarding dental. Med-QUEST Division explained that the HAR will be updated after CMS approves the benefit.

Comments and questions were also received by MHAC members regarding HCBS ARPA spending activities for the HCBS Rate Study and the Person-Centered Planning. A question was raised about whether the rate increases would be ready as they want to support this ask when this budget request goes before the legislature. General comments were provided regarding the Person-Centered Planning and how MQD can ensure that this becomes part of the culture in providing services to the Medicaid population. Med-QUEST Division explained that they have a consultant working with the State for the next 2 years to assist with incorporating this concept through trainings with the health plans and this focus is not just for HCBS members but all members in Medicaid.

Comments and questions were received by MHAC members and the public regarding the State Plan Amendment (SPA) updates. A question was raised by a MHAC member regarding the licensure for a mid-wife in the State Plan and if a mid-wife will have hospital privileges to be considered a PCP. Med-QUEST Division explained that these issues still need to be worked out and that the mid-wife will most likely be viewed as a specialist and not a PCP. A member from

the public asked about the status of the CAMHD SPA. Med-QUEST Division explained that this SPA is in the Request for Additional Information (RAI) period so the 90-day clock has stopped. Med-QUEST Division will address CMS' issues and respond to the RAI.

MHAC meeting, December 14, 2022

Med-QUEST Division presented updates on information regarding the Social Determinants of Health (SDOH) Transformation Plan, Dental Services, and the Upcoming Legislative Session. The MQD also presented on State Plan Amendment updates for Pregnant Woman and Unborn, and MQD Member Communications on the Public Health Emergency Unwinding process. Comments and questions were received from both the MHAC members and the public regarding the information presented.

Questions were received by both MHAC and the public regarding the SDOH Transformation Plan. A question was raised by a MHAC member asking how will this Transformation Plan work with the existing plans in place with the health plans? Med-QUEST Division explained that each health plan contracted with the MQD is required to have their own SDOH plan and some of them are performing this function in different ways so MQD is looking for opportunities to streamline this work to make it easier to follow for both providers and members. Another question was raised regarding the funding for this project. Med-QUEST Division explained that it will be adding in certain SDOH services in the new 1115 waiver for 2024 and will finance these services through the waiver. A member from the public asked how they can reach out for public comment on this matter in January. Med-QUEST Division explained that this issue will be available for public comment soon and MQD is working on setting this up.

Questions were received by MHAC regarding Dental Services. The MHAC member asked if there were certain conditions in the dental benefit package that would allow for additional cleanings such as diabetes or pregnancy and would that require a prior authorization. Med-QUEST Division explained that if the services are medically necessary then the provider can contact HDS for additional services. Med-QUEST Division also mentioned that updates were made to the fee for service provider manual and is available on the State MQD website.

Questions were received by MHAC regarding the Upcoming Legislative Session asking if MQD is looking for support on any specific bills. Med-QUEST Division explained that it has 2 bills regarding hospitals and nursing facilities, and anyone can submit comments or testimony.

Questions were received by MHAC regarding the Licensed Mid-Wife SPA regarding whether there are technical concerns from CMS about how the Mid-Wife is defined as there are different types of mid-wives licensed in our state. Med-QUEST Division will reach out separately to this MHAC member to consult with them on this matter.

A comment was received by MHAC regarding the PHE unwinding and the movie theater campaign. Med-QUEST Division showed a video clip about the PHE unwind and the video was well received by the MHAC member.

III. Performance Metrics

A. Impact of the Demonstration

1. Providing Insurance Coverage to Beneficiaries and the Uninsured Population

Total enrollment as of 12/26/22: 461,789

2. Outcomes of Care, Quality of Care, Cost of Care, and Access to Care

There is no reporting on the above for this quarter.

B. Results of Beneficiary Satisfaction Surveys (if conducted)

A Consumer Assessment of Healthcare Providers and Systems (CAHPS) was conducted for adult members of all five Quest Integration (QI) plans between February to May 2022. Results were shared by MQD's EQRO in November 2023. The Hawaii CAHPS had a 18.4% response rate which was higher than the national response rate (15.4%). For most composite measures and global ratings, there were no statistically significant differences compared to the 2020 CAHPS. However, there were some areas including "Rating of Personal Doctor" and "How Well Doctors Communicate" that showed significantly lower ratings. These results have been shared with Health Plans and internal to MQD, including the internal quality committee and collaborative quality workgroups, to identify the key drivers for these decreases and improve member satisfaction in these domains.

C. Results of Grievances and Appeals (from Health Plans)

Nearly all grievances and appeals were timely resolved. The trend has continued since last quarter.

Туре	Total	Timely Resolved* # (%)	Resolved in Favor of Beneficiaries** # (%)
Grievances	521	457 (97.0%)	184 (37.2%)
Appeals	368	264 (96.7%)	52 (19.0%)

^{*}Timely is defined as within 30 days for standard grievances and appeals, within 14 days for expedited appeals, and within the approved extension time period for grievances and appeals with approved extensions. Denominator excludes grievances and appeals received within 30 days of the end of the reporting period with no resolution (or 3 days for expedited appeals).

^{**}Denominator excludes appeals for which no decision has been made.

IV. Budget Neutrality and Financial Reporting Requirements

A. Financial Performance of the Demonstration

For the quarter ending 9/30/2023, Hawaii has continued to accrue budget neutrality savings, which is shown in the Budget Neutrality Summary attached to this report. In addition, the Hypothetical Expansion eligibility category has continued to accrue budget neutrality savings. The Demonstration continues to project budget neutrality savings in future years.

B. Updated Budget Neutrality Workbook

The Budget Neutrality Workbook for the quarter ending 12/31/2022 will be submitted by the 2/28/2023 deadline. The Budget Neutrality Workbook for the quarter ending 9/30/2022 is attached (Attachment B).

C. Quarterly and Annual Expenditures

Expenditures for the quarter ending 12/31/2022 were reported on the CMS-64 and certified on 1/30/2023. A summary of expenditures is shown on the attached Schedule C for the quarter ending 12/31/2022.

D. Administrative Costs

Despite record highs in enrollment, there have not been significant increases in Hawaii's administrative costs for the quarter ending 12/31/2022. Cumulative administrative expenditures can be found on the attached Schedule C.

V. Evaluation Activities and Interim Findings

A. Progress Summary of Evaluation Activities

1. Key Milestones Accomplished

Med-QUEST Division released a new reporting package which will assist with monitoring evaluation goals for the 1115 waiver. Health Plans submitted another round of Community Integration Services (CIS), Long-Term Services and Supports (LTSS), Special Health Care Needs, Value-Driven Health Care, and Primary Care reports with data quality improving compared to previous quarters. However, MQD

and the University of Hawaii (UH) Evaluation team are still providing targeted technical assistance and engaging with the Health Plans to improve data quality across all reports.

The UH Evaluation Team held a CIS rapid cycle assessment on December 1st, 2022.

2. Challenges Encountered and How They Were Addressed

Acceptable data quality of the reports still remain a challenge. Med-QUEST Division and the UH Evaluation Team are continuing to meet with Health Plans at a greater frequency to better understand how the Health Plans are pulling this information and assisting the Health Plans with mapping the right data to specific fields in the report. Med-QUEST Division developed an aggressive schedule and strategy to ensure that the reports will be submitted with acceptable data quality standards in the near future.

3. Interim Findings (when available)

CIS

Some select successes in implementation include:

- 12 housing service providers are onboarded
- CIS-enrolled members needs are being met
- Improved data quality in reports allowing for enhanced monitoring of program implementation and success
- Health Plan engagement in evaluation process

Select barriers in implementation include:

- Inconsistent information and data sharing between agencies and housing service providers due to siloed and non-interoperable systems
- Managed care plans still optimizing best workflows
- Housing service providers learning how to bill for CIS services

4. Status of Contracts with Independent Evaluators (if applicable)

Contract is executed for the University of Hawaii Evaluation team for CY 2022 with plans to extend for CY 2023.

5. Status of Institutional Review Board Approval (if applicable)

Not Applicable

6. Status of Study Participant Recruitment (if applicable)

Not Applicable

7. Result or Impact of the Demonstration Programmatic Area Defined by CMS that is Unique to the Demonstration Design or Evaluation Hypotheses

See progress notes above. Unique results and impact on the Demonstration will be provided in upcoming reports.

VI. Med-QUEST Division Contact

Jon D. Fujii Health Care Services Branch (HCSB) Administrator 601 Kamokila Blvd., Suite 506A Kapolei, HI 96707

Phone: 808-692-8083 Fax: 808-692-8087 The Budget Neutrality Reporting Period dropdown menu allows for selection of a specific reporting period, by Demonstration Year. By changing these settings, you change the view for which Demonstration Years will be used in calculating Budget Neutrality. Selecting the Reset to Defaults' button will reset the Reporting DY visues back to the demonstration's counter Period of Performance.

Budget Neutrality Reporting Start DY Budget Neutrality Reporting End DY	26 30	1							
Actuals + Projected									
Vithout-Waiver Total Expenditures									
				26	27	28	29	30	Total
ledicaid Per Capita									
G 1 - Children	1	Total PMPM	s	\$448.48	\$452.96	\$457.49	\$462.07	\$466.69	
		Mem-Mon		1,403,508	1,539,475	1,624,640	1,665,004	1,706,629	
G 2 - Adults	2	Total	s	389.312.838 \$	472.902.030 S	534.517.133 \$	557.755.942 \$	592.854.097	
		Mem-Mon		420,665	492,750	537,079	540,435	553,945	
EG 3 - Aged	3	Total	\$	658,889,243 \$	764,674,765 \$	883,519,979 \$	727,880,659 \$	760,156,997	
		PMPM Mem-Mon		\$1,939.17 339,779	\$2,005.11 381,363	\$2,073.28 426,146	\$2,143.77 339,533	\$2,216.66 342,929	
EG 4 - Blind/Disabled	4	Total	s	757,508,006 \$	846,263,757 \$	901,246,138 \$	980,956,602 \$	1,034,360,778	
		PMPM Mem-Mon		\$2.646.76 286.202	\$2.763.22 306.260	\$2.884.80 312.412	\$3.011.73	\$3.144.25	
TOTAL	-	ment-mon							14 498 636
			1.0	2,430,100,304 9	2,701,101,140 3	3,062,035,003 \$	3,030,541,601	3,103,030,000 3	14,450,030,
Vith-Waiver Total Expenditures	1	1	Т						TOTAL
Medicaid Per Capita	-		╁		27	28	29	30	
G 1 - Children	1 2		s s	393,604,189 \$ 167,196,359 \$	422,427,541 \$ 205,539,067 \$	429,841,674 \$ 226,798,849 \$	432,076,554 \$ 246,754,662 \$	447,307,253 262 281 700	\$5,585,612 \$3,162,076
G 3 - Aged	3		s	398.056.758 \$	459.050.895 S	496.263.747 \$	475.772.123 \$	502.750.842	\$6.240.297
	4								
		1	\$	1,436,771,372 \$	1,613,184,161 \$	1,677,381,327 \$	1,803,791,033 \$	1,897,628,856 \$	8,428,756,
avings Phase-Down		1	1						TOTAL
ledicald Per Capita	-	Savinne Phase, Down	-	26	27	28	29	30	
G 1 - Children	1	Without Waiver	s	629.445.268 \$	697.320.596 S	743.256.554 \$	769.348.398 \$	796.466.688	
		veitn waiver	\$	235,841,079 \$	274,893,055 \$	313,414,880 \$	337,271,844 \$	349,159,435	
		I.	s	25% 176.880.809 \$	25% 206.169.791 \$	25% 235.061.160 \$	25% 252.953.883 \$	25% 261.869.576	
G 2 - Adults	2	Savings Phase-Down Without Waiver	\$	389,312,838 \$	472,902,030 \$	534,517,133 \$	557,755,942 \$	592,854,097	
		With Waiver	\$ S	167,196,359 \$	205,539,067 \$ 267.362.963 \$	226,798,849 \$ 307.718.284 \$	246,754,662 \$	262,281,700	
		l	s	25%	25%	25%	25%	25%	
	1	Savings Phase-Down	ľ						
	3	Without Waiver With Waiver	\$	398,056,758 \$	459,050,895 \$	496,263,747 \$	727.880.659 \$ 475,772,123 \$	502.750.842	
hase-Down Percentage		l	\$	25%	305,623,870 \$ 25%	25%	25%	25%	
		Savinas Phase-Dove	s	195.624.364 \$	229.217.903 S	290.442.174 \$	189.081.402 S	193.054.616	
G 4 – Blind/Disabled	4	Without Waiver With Waiver	\$	757,508,006 \$ 477,914,067 \$	846,263,757 \$ 526,166,658 \$	901,246,138 \$ 524,477,057 \$	980,956,602 \$ 649,187,694 \$	1,034,360,778	
			\$	279,593,939 \$	320,097,099 \$	376,769,081 \$	331,768,908 \$	349,071,717	
avings Reduction		ĺ	\$	25% 209,695,454 \$	25% 240,072,825 \$	25% 282,576,810 \$	25% 248,826,681 \$	25% 261,803,788	
otal Reduction			\$	748,787,986 \$	875,982,741 \$	1,038,868,857 \$	924,112,926 \$	964,657,278 \$	4,552,409
ASE VARIANCE			\$	249,595,995 \$	291,994,247 \$	346,289,619 \$	308,037,642 \$	321,552,426 \$	1,517,469
115A Dual Demonstration Savinos (state preliminary estimate)								s	
ET VARIANCE								\$	1,517,469.
IET VARIANCE								s	1,517,469,
IET VARIANCE	<u> </u>			26	27	28	29	30	1,517,469.
LET VARIANCE Lumulative Target Limit Lumulative Target Percentage (CTP)	<u> </u>		s	2.0%	1.5%	1.0%	0.5%	30	1,517,469,
IET VARIANCE Lumulative Target Limit Lumulative Target Percentage (CTP) Lumulative Budget Neutrality Limit (CBNL)			\$ \$		1.5%	1.0%		s	1,517,469,
LET VARRANCE Lumuladive Target Limit Lumuladive Target Percentage (CTP) Lumuladive Barget Percentage (CTP) Lumuladive Barget Neutrality Lumul (CBNL) Ullowed Cumuladive Variance (= CTP X CBNL) Lichal Cumuladive Variance (= CTP X CBNL)			\$ \$	2.0%	1.5% 3,591,545,775 \$	1.0%	0.5% 7,727,045,397 \$	30	1,517,469,
LET VARRANCE Lumuladive Target Limit Lumuladive Target Percentage (CTP) Lumuladive Barget Percentage (CTP) Lumuladive Barget Neutrality Lumul (CBNL) Ullowed Cumuladive Variance (= CTP X CBNL) Lichal Cumuladive Variance (= CTP X CBNL)			1	2.0% 1,686,367,368 \$ 33,727,347 \$	1.5% 3,591,545,775 \$ 53,873,187 \$	1.0% 5,615,216,722 \$ 56,152,167 \$	0.5% 7,727,045,397 \$ 38,635,227 \$	30 9,946,226,679	1,517,469,
IET VARRANCE Limitulative Target Limit Limitulative Target Percentiage (CTP) Limitulative Doublet Neutrality Limit (CBNL) Roboro Comunitative Nationace (CTP) X CBNL) Lottus (Cumulative Variance (Positive © Oversoendino) a Corrective Action Plan needed?			1	2.0% 1,686,367,368 \$ 33,727,347 \$	1.5% 3,591,545,775 \$ 53,873,187 \$	1.0% 5,615,216,722 \$ 56,152,167 \$	0.5% 7,727,045,397 \$ 38,635,227 \$	30 9,946,226,679	1,517,469,
LET VARIANCE Lumidative Target Limit Lumidative Target Percentage (CTF) Lumidative Target Percentage (CTF) Lumidative Target Percentage (CTF) Lumidative Cardiality Limit (CRNL) Indicated Cumidative Variance (CTF) CCRNL) Latal Cumidative Variance (Positive = Oversoendino) a Corrective Action Plan needed? VEPOTHETICALS TEST 1			1	2.0% 1,686,367,368 \$ 33,727,347 \$	1.5% 3,591,545,775 \$ 53,873,187 \$	1.0% 5,615,216,722 \$ 56,152,167 \$	0.5% 7,727,045,397 \$ 38,635,227 \$	30 9,946,226,679	1,517,469,
ET VARIANCE umulative Target Limit umulative Target Percentage (CTP) umulative Target Percentage (CTP) umulative Target Percentage (CTP) umulative Douget Nearfailty Limit (CRNL) lower Cumulative Variance (CTP) CCRNL) class Cumulative Variance (Positive = Oversoendino) a Corrective Action Plan needed? YPOTHETICALS TEST 1			1	2.0% 1,686,367,368 \$ 33,727,347 \$ (249,595,995) \$	1.5% 3.591,545,775 \$ 53,673,187 \$ (541.590.242) \$	1.0% 5.615.216,722 \$ 56,152,167 \$ (887.879.861) \$	0.5% 7,727,045,397 \$ 38,835,227 \$ (1.195,917,503) \$	30 9,946,226,679 (1.517,469,929)	
ET VARRANCE umulative Target Limit umulative Target Eventrace (CTF) umulative Busele Neutraliv Limit (CBNL) lowed Cumulative Variance (* CTP X CBNL) chause Cumulative Variance (* Positive * Oversoendina) a Corrective Action Plan needed? YPOTHETICALS TEST 1 Hithout Walver Total Expenditures ypothetical 1 Per Capita			s	2.0% 1,686,367,368 \$ 33,727,347 \$ (249,595,995) \$	1.5% 3.591,545,775 \$ 53,673,187 \$ (541.590.242) \$	1.0% 5.615.216.722 \$ 56.152.167 \$ (887.879.861) \$	0.5% 7,727,045,397 \$ 38,635,227 \$ (1.195,917,503) \$	30 9,946,226,679 (1,517,469,929)	1,517,469
ET VARRANCE umulative Target Limit umulative Target Eventrase (CTF) umulative Busele Neutraliv Limit (CBNL) lowed Cumulative Variance (* CTP X CBNL) chause Cumulative Variance (* PLO X CBNL) a Correctione Action of Plan Insended? YPOTHETICALS TEST 1 Hithout Walver Total Expenditures ypothetical 1 Per Capita	1	Total	1	2.0% 1,686.367,388 \$ 33,727,347 \$ (249.595.995) \$	3,591,545,775 \$ 53,873,187 \$ (541,590,242) \$	1.0% 5.615.216,722 \$ 56,152.167 \$ (687.879.861) \$	7,727,045,397 \$ 38,635,227 \$ (1.195,917,503) \$	30 9,946,226,679 (1,517,469,929) 30 1,826,368,919	
ET VARRANCE umulative Target Limit umulative Target Eventrase (CTF) umulative Busele Neutraliv Limit (CBNL) lowed Cumulative Variance (* CTP X CBNL) chause Cumulative Variance (* PLO X CBNL) a Correctione Action of Plan Insended? YPOTHETICALS TEST 1 Hithout Walver Total Expenditures ypothetical 1 Per Capita	1	Total PMPM Men-Mon	s	2.0% 1,686,367,368 \$ 33,727,347 \$ (249,595,995) \$	1.5% 3.591,545,775 \$ 53,673,187 \$ (541.590.242) \$	1.0% 5.615.216.722 \$ 56.152.167 \$ (887.879.861) \$	0.5% 7,727,045,397 \$ 38,635,227 \$ (1.195,917,503) \$	30 9,946,226,679 (1,517,469,929)	
ET VARRANCE umulative Target Limit umulative Target Percentage (CTP) umulative Sobusel Neutraline (Limit (CBNL) lowed Cumulative Variance (CTP) A CBNL) conscious Cumulative Variance (Positive Noversoendino) a corrective Action Plan needed? YPOTHETICALS TEST 1 Itihout-Walver Total Expenditures ypothetical 1 Per Capita 6 5 – Group VIII	1	PMPM	s	2.0% 1.686.367,368 \$ 33,727,347 \$ (249.595.995) \$	1.5% 3.591,545,775 \$ 53,873,187 \$ (541.590.242) \$	1.0% 5.615.216.722 \$ 56.152.167 \$ (887.879.861) \$	0.5% 7.727,045,397 38,635,227 \$ (1.195,917,503) \$ 29 1,700,212,480 \$1,035,20	30 9,946,226,679 (1,517,469,929) 1,826,388,919 \$1,084,99	TOTAL
ET VARIANCE umulative Target Limit umulative Target Percentage (CTP) umulative Busget Neutrality Limit (CBNL) towed Cumulative Variance (r CTP X CBNL) towed Cumulative Variance (r CTP X CBNL) a Corrective Action Plan needed? YPOTHETICALS TEST 1 Illihout-Walver Total Expenditures ypothetical 1 Per Capita 5 - Group Vili OTAL	1	PMPM	s	2.0% 1,696.37.388 \$ 33,727.347 \$ (249.595.995) \$ 26 1,299.058,737 \$ \$899.37 1,411.053	1.5% 3.591,545,775 53,873,187 \$ (541.590,242) \$ 27 1,712,257,751 \$ 842,54 1,816,642	1.0% 5.615.216,722 56.152,167 \$ (887.879.861) \$ 28 2.065.875.699 \$ 5087.78 2.091.433	0.5% 7.727 (45.397 8 38.635.27 \$ (1.195.917.503) \$ 29 1.700.212.480 \$ 51.035.20 1.642.400	30 9,946,226,679 - (1.517,469,929) 30 1,826,368,919 31,064,89 1,683,460	TOTAL
ET VARRANCE umulative Target Limit umulative Target Percentage (CTP) umulative Target Percentage (CTP) umulative Target Percentage (CTP) umulative Disaget Neutralive Jurist (CRNL) lowed Cumulative Variance (** CTP X CRNL) lowed Cumulative Variance (** CTP X CRNL) lowed Cumulative Variance (** CTP X CRNL) a Corrective Action Plan needed? YPOTHETICALS TEST 1 (Ithout-Walver Total Expenditures ypothetical 1 Per Capita 3 - Gross VII DTAL Uth. Walver Total Expenditures	1	PMPM	s	2.0% 1,696.37.388 \$ 33,727.347 \$ (249.595.995) \$ 26 1,299.058,737 \$ \$899.37 1,411.053	1.5% 3.591,545,775 53,873,187 \$ (541.590,242) \$ 27 1,712,257,751 \$ 842,54 1,816,642	1.0% 5.615.216,722 56.152,167 \$ (887.879.861) \$ 28 2.065.875.699 \$ 5087.78 2.091.433	0.5% 7.727 (45.397 8 38.635.27 \$ (1.195.917.503) \$ 29 1.700.212.480 \$ 51.035.20 1.642.400	30 9,946,226,679 - (1.517,469,929) 30 1,826,368,919 31,064,89 1,683,460	TOTAL
ET VARIANCE unuslative Target Limit unuslative Target Limit unuslative Target Preventance (CTP) unuslative Target Reventance (CTP) unuslative Variance (CTP) unuslative Variance (CTP) X CBNL) chaid Cumulative Variance (Positive & Overscendinc) a Correction Action Plan meeter? VPOTHETICALS TEST 1 tithout Waive Total Expenditures positivated Per Capita 3.5 - Crosp VIII STAL tith Waiver Total Expenditures vpothetical 1 Per Capita	L T	PMPM	s	2.0% \$ 1,686.367,368 \$ 2,773,47 \$ (249.595.995) \$ 26 1.269.058.737 \$ 359.37 \$ 1,411.053 \$ 1,269.058,737 \$ 26	1.5% 3.591,545,776 \$ 53,871,587 \$ (541,590,242) \$ 27 1,712,257,751 \$ 8142,54 1,816,642 51,712,257,751	1.0% 5.615.216,722 \$ 56.152.167 \$ (887.879.861) \$	0.5% 7.727.045.397 36.635.272 \$ (11.95.917.503) \$ 29 1.700.212.480 \$ 51.035.20 1.642.400 51.700.212.480	30 9.946.226.679 - (1.517.469.929) 30 1.826.368.919 51.084.89 1.683.460 51.826.368.919	TOTAL \$8,573,773
ET VARIANCE umulative Target Limit umulative Target Limit umulative Target Perentiane (CTP) umulative Target Perentiane (CTP) umulative Target Perentiane (CTP) umulative Variane (w CTP X CBNL) bowed Cumulative Variance (w CTP X CBNL) classic Cumulative Variance (w CTP X CBNL) classic Cumulative Variance (w CTP X CBNL) classic Cumulative Variance (w CPP X CBNL) very POTHETICALS TEST 1 thou-Waiver Total Expenditures vporthetical 1 Per Capita 35 - Group Vill Tith-Limit Variance (w Capita 35 - Group Vill 1 Per Capita	1	PMPM	s	2.6% 1,685,367,368 \$ 33,727,347 \$ (249,595,995) \$ 26 1,269,058,737 \$ 25,059,059,737 1,411,053 51,269,058,737 2 58,058,737 25 58,058,737 25 58,058,737 25	1.5% 3.591,542,775 3.3671,367 3.591,542,775 3.592,542 1.712,257,751 1.712,257,751 1.816,642 27 27 27 27 27 27 27 27 27 27 27 27 27	1.0% 5.515.215.722 \$.515.215.72 \$.515.215.	0.5% 7,727,046.327 \$ 38,635,227 \$ (1.195.917.503) \$ 29 1,700,217.460 \$ \$1,050.50 1,842.400 29 29 \$953,114.884	30 9,946,226,679 9,946,226,679 (1,517,469,929) 1,626,368,919 31,084,99 51,626,368,919 30 51,626,368,919 30 51,626,368,919	TOTAL \$8,573,773
ET VARIANCE mulative Target Limit mulative Target Percentage (CTP) mulative Target Percentage (CTP) mulative Target Percentage (CTP) mulative Target Percentage (TCP) mulative Target Percentage (TCP) provided Countidative Variance (= CTP X CDIN.) tata Countagive Variance (= CTP X CDIN.) tata Countidative Variance (= CTP X CDIN.) tata Countagive Variance (= Overscendinc) a Corrective Action Plan needed? POTHETICALS TEST 1 tithout-Waiver Total Expenditures providerical 1 Per Capita 5 - Group VIII 15 - Group VIII 35 - Group VIII 36 - Group VIII 375AL	L T	PMPM	\$	2.0% 1,685,367,368 \$ 33,727,367 \$ (249,565,995) \$ 28 1,289,058,737 \$ 889,37 \$ 1,411,55 \$ 1,411,55 \$ 1,411,55 \$ 542,883,100 \$	1.5% 3.591.542.775 \$ 53.671.787 \$ (541.590.242) \$ 27 1.712.257,761 \$ 8322.54 1.912.257,761 \$ 5373.642.680 \$ 673,842.680 \$	1.0% 5.515.215.722 \$.50.152.107 \$.50.152.1	0.5% 7,727,045,337 \$ 38,635,277 \$ (1.196,917,503) \$ (1.196,917,503) \$ 29 1,700,212,480 \$ 51,032,400 1,642,400 51,700,212,480 29 \$953,114,884 \$	39 9,946,226,679 9,946,226,679 (1.517,469,929) 1,826,368,919 \$1,684,98 \$1,68	TOTAL \$8,573,773 TOTAL 4,524,426
ET VARIANCE umulative Target Limit umulative Target Percentage (CTP) umulative Turget Percentage (CTP) umulative Busget Neutrality Limit (CBNL) towed Cumulative Variance (= CTP X CBNL) towed Cumulative Variance (= CTP X CBNL) a Corrective Action Plan needed? YPOTHETICALS TEST 1 (tithout-Waiver Total Expenditures ypothetical 1 Per Capits 0 5 - Group VIII DTAL THIN Waiver Total Expenditures ypothetical 1 Per Capits 0 5 - Group VIII DTAL	L T	PMPM	s	2.6% 1,685,367,368 \$ 33,727,347 \$ (249,595,995) \$ 26 1,269,058,737 \$ 25,059,059,737 1,411,053 51,269,058,737 2 58,058,737 25 58,058,737 25 58,058,737 25	1.5% 3.591,542,775 3.3671,367 3.591,542,775 3.592,542 1.712,257,751 1.712,257,751 1.816,642 27 27 27 27 27 27 27 27 27 27 27 27 27	1.0% 5.515.215.722 \$.515.215.72 \$.515.215.	0.5% 7,727,046.327 \$ 38,635,227 \$ (1.195.917.503) \$ 29 1,700,217.460 \$ \$1,050.50 1,842.400 29 29 \$953,114.884	30 9,946,226,679 9,946,226,679 (1,517,469,929) 1,626,368,919 31,084,99 51,626,368,919 30 51,626,368,919 30 51,626,368,919	TOTAL \$8,573,773 TOTAL 4,524,426
ET VARBAKE umulative Target Limit umulative Target Enercatage (CTP) umulative Target Percentage (CTP) umulative Target Percentage (CTP) umulative Dudget Neutrality Limit (CDNL) towed Cumulative Variance (** CTP X CDNL) a Corrective Action Plan needed? **POTHETICALS TEST 1 Ithhout-Waiver Total Expenditures ypothetical 1 Per Capita 3 - Gove Vil 1th Waiver Total Expenditures ypothetical 1 Per Capita 3 - Gross Vill 5 - Gross Vill 6 - Gross Vill 7 - Gross Vill	L T	PMPM	\$	2.0% 1,685,367,368 \$ 33,727,367 \$ (249,565,995) \$ 28 1,289,058,737 \$ 889,37 \$ 1,411,55 \$ 1,411,55 \$ 1,411,55 \$ 542,883,100 \$	1.5% 3.591.542.775 \$ 53.671.787 \$ (541.590.242) \$ 27 1.712.257,761 \$ 8322.54 1.912.257,761 \$ 5373.642.680 \$ 673,842.680 \$	1.0% 5.515.215.722 \$.50.152.707 \$.50.152.7	0.5% 7,727,045,337 \$ 38,635,277 \$ (1.196,917,503) \$ (1.196,917,503) \$ 29 1,700,212,480 \$ 51,032,400 1,642,400 51,700,212,480 29 \$953,114,884 \$	39 9,946,226,679 9,946,226,679 (1.517,469,929) 1,826,368,919 \$1,684,98 \$1,68	TOTAL \$8,573,773 TOTAL 4,524,426
ET VARIANCE umulative Target Limit umulative Target Everentace (CTP) umulative Target Percentace (CTP) umulative Target Neutrality Limit (CRNL) lowed Cumulative Variance (= CTP X CRNL) tatus Cumulative Variance (= CTP X CRNL) tatus Cumulative Variance (= Positive = Oversoendino) a Corrective Action Plan needed? YPOTHETICALS TEST 1 lithout Walver Total Expenditures ypothetical 1 Per Capita 3- Group Vill 3TAL Ith Walver Total Expenditures ypothetical 4 Per Capita 3- Group Vill 3TAL YPOTHETICALS VARIANCE 1 YPOTHETICALS VARIANCE 1	L T	PMPM	\$	2.0% 1,685,367,368 \$ 33,727,367 \$ (249,565,995) \$ 28 1,289,058,737 \$ 889,37 \$ 1,411,55 \$ 1,411,55 \$ 1,411,55 \$ 542,883,100 \$	1.5% 3.591.542.775 \$ 53.671.787 \$ (541.590.242) \$ 27 1.712.257,761 \$ 8322.54 1.912.257,761 \$ 5373.642.680 \$ 673,842.680 \$	1.0% 5.515.215.722 \$.50.152.707 \$.50.152.7	0.5% 7,727,045,337 \$ 38,635,277 \$ (1.196,917,503) \$ (1.196,917,503) \$ 29 1,700,212,480 \$ 51,032,400 1,642,400 51,700,212,480 29 \$953,114,884 \$	39 9,946,226,679 9,946,226,679 (1.517,469,929) 1,826,368,919 \$1,684,98 \$1,68	TOTAL \$8,573,773 TOTAL 4,524,426
ET VARIANCE umulative Target Limit umulative Target Percentane (CTP) umulative Busele Neutraliv Limit (CTP) umulative Busele Neutraliv Limit (CTP) umulative Busele Neutraliv Limit (CTP) umulative Variance (* CTP X CBNL) tatus Carmelate Variance (* DE) a Corrective Action Plan needed? YPOTHETICALS TEST 1 Itihous Waiver Total Expenditures ypothetical 1 Per Capita 3TAL Itih. Waiver Total Expenditures ypothetical 4 Per Capita 35 - Group VIII 3TAL YPOTHETICALS VARIANCE 1 YPOTHETICALS VARIANCE 1	L T	PMPM	\$	267. 269. 33.727.347 \$ 1,596.397.39 \$ 33.727.347 \$ 1249.595.995) \$ 26 1.269.056,737 \$ \$699.37 1,411.053 \$1,269.056,737 26 642,883.100 642,883.100 \$	15% 3,591,546.7778 \$ 53,873,187 \$ (551,500,242) \$ 27 27 1,112,257,751 \$ \$3042,54 1,816,642 1,816,642 27 27 27 27 27 27 27 27 27 2	1702 5,615,21672 8 56,152,167 8 56,152,167 8 (887,879,861) \$ 28 2,056,875,689 \$ 5,067,76 2,061,433 12,065,875,689 \$1,030,749,731 1,035,749,731 \$	0.5% 7.727.045.097 \$ 7.727.045.097 \$ 88,635.227 \$ (1.195.917.503) \$ 29 1.700.212.480 \$ 51,035.20 1,642.400 31,700.212.480 953,114.894 953,114.894 953,114.894 \$	30 9,946,226,679 9,161,517,469,929) 1,623,388,919 1,623,460 1,623,635,987 1,023,835,987 1,023,835,987 1,023,835,987 1,023,835,987 1,023,835,987	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347
ET VARIANCE umulative Target Limit umulative Target Limit umulative Target Limit proportion (CTP) umulative Bucher (Marchine) (Limit (DRNL) lowed Cumulative Variance (* CTP X CRNL) chauditive (*	1	PMPM Mem-Hon	\$	2.6% 2.7% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8	15% 3.591545.73 8 3.591545.73 8 3.591545.73 8 3.673.187 8 (541.590.242) \$ 27 1.712.257.751 \$ 5842.54 1.816.642 81,712.257.751 27 27 27 2873,842.680 \$ 833,842.680 \$	1,000 5,615,2167,227, 8 56,152,167, 8 56,152,167, 8 (887,879,861) \$ 28 2,056,875,689 5867,78 2,091,433 \$2,065,875,689 \$1,030,749,731 1,030,749,731 1,030,749,731 1,035,125,959 \$	0.5% 7,727,046.397 \$ 36,635,227 \$ (1.195,917,503) \$ 29 1,105,212,480 \$ 51,035,20 1,542,400 \$ 11,700,212,480 \$ 31,700,212,480 \$ 47,700,212,480 \$ 47,700,2	30 9.946.226,679 9.946.226,679 (1.517.469.929) 1.826.386.919 1.826.386,919 30 51.826,386,919 30 51.826,386,919 30 51.823,85,987 1.623,835,987 30 30	TOTAL \$8,573,773 TOTAL 4,524,426
ET VARIANCE umulative Target Devotrace (CTF) umulative Target Devotrace (CTF) umulative Target Percentace (CTF) umulative Target Newtrace (CTF) umulative Variance (CTF) umulative Variance (CTF) X CBNL) chaula Cumulative Variance (Positive & Oversoendino) a Corrective Action Plan needed? PPOTHETICALS TEST 1 tithout Waive Total Expenditures ypothetical 1 Per Capita 35 — Group VIII STAL IIII-Waiver Total Expenditures ypothetical 1 Per Capita 55 — Group VIII PPOTHETICALS VARIANCE 1 PPOTHETICALS VARIANCE 1 PPOTHETICALS TEST 2 tithout Waiver Total Expenditures ypothetical 2 Per Capita 55 — Group VIII PPOTHETICALS VARIANCE 1 TYPOTHETICALS TEST 2 tithout Waiver Total Expenditures	L T	PMPM Mem-Mon Total PMPM	\$	267. 269. 33.727.347 \$ 1,596.397.39 \$ 33.727.347 \$ 1249.595.995) \$ 26 1.269.056,737 \$ \$699.37 1,411.053 \$1,269.056,737 26 642,883.100 642,883.100 \$	15% 3,591,546.7778 \$ 53,873,187 \$ (551,500,242) \$ 27 27 1,112,257,751 \$ \$3042,54 1,816,642 1,816,642 27 27 27 27 27 27 27 27 27 2	1702 5,615,21672 8 56,152,167 8 56,152,167 8 (887,879,861) \$ 28 2,056,875,689 \$ 5,067,76 2,061,433 12,065,875,689 \$1,030,749,731 1,035,749,731 \$	25% 7,727,046,397 8 38,635,227 8 (1.195,917,503) \$ (1.195,917,503) \$ 29 1,700,212,480 \$ 51,050,212,480 \$ 51,050,212,480 \$ 51,700,212,480 \$ 51,700,212,480 \$ 51,700,212,480 \$ 51,700,212,480 \$ 29 29 29 4,516,007 \$ 51,333,59	30 9,946,226,679 9,946,226,679 (1,517,469,929) 1,826,368,919 1,826,368,919 31,624,368,919 30 \$1,023,835,987 1,023,835,987 1,023,835,987 30 802,632,932 \$1,826,926 \$1,826 \$1,826,926 \$1	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347
ET VARIANCE mulative Target Percentage (CTP) mulative Variance (Positive + Oversoendina) a Corrective Action Pean needed? PPOTHETICALS TEST 1 tithout Waiver Total Expenditures ypothetical 1 Per Capita 35 — Group VIII STAL HITH Waiver Total Expenditures ypothetical 1 Per Capita 55 — Group VIII PPOTHETICALS VARIANCE 1 PPOTHETICALS VARIANCE 1 PPOTHETICALS VARIANCE 1 PPOTHETICALS TEST 2 tithout Waiver Total Expenditures ypothetical 2 Per Capita	1	PMPM Mem-Hon	\$	269.058,737 \$ 269.058,737 \$ 249.595,995) \$ 28 1.269.058,737 \$ 5899.37 1,411.053 51,269.058,737 26 626,175,637 \$	15% 3,591,546,778 \$ 53,873,187 \$ (541,590,242) \$ 27 1,712,257,751 \$ \$842,54 1,816,642 1,816,642 27 27 27 27 27 27 27 27 27 2	1700 5,915,21072 \$ 69,152,167	0.5% 7,727,046.397 \$ 36,635,227 \$ (1.195,917,503) \$ 29 1,105,212,480 \$ 51,035,20 1,542,400 \$ 11,700,212,480 \$ 31,700,212,480 \$ 47,700,212,480 \$ 47,700,2	30 9.946.226,679 9.946.226,679 (1.517.469.929) 1.826.386.919 1.826.386,919 30 51.826,386,919 30 51.826,386,919 30 51.823,85,987 1.623,835,987 30 30	TOTAL \$8,973,773 TOTAL 4,524,428 4,049,347
ET VARIANCE umulative Target Limit umulative Target Perventane (CTP) umulative Target Perventane (CTP) umulative Target Perventane (CTP) umulative Target Perventane (CTP) umulative Variance (CTP) umulative Oversoendino) a Corrective Action Plan needed? yPOTHETICALS TEST 1 ithout Waiver Total Expenditures uporthetical 1 Per Capita 35 — Croup VIII 37AL UPOTHETICALS VARIANCE 1 VPOTHETICALS VARIANCE 1 VPOTHETICALS TEST 2 ithout Waiver Total Expenditures ypothetical 2 Per Capita 36 — CIS	1	PMPM Mem-Mon Total PMPM	\$	269.058,737 \$ 269.058,737 \$ 249.595,995) \$ 28 1.269.058,737 \$ 5899.37 1,411.053 51,269.058,737 26 626,175,637 \$	15% 3,591,546,778 \$ 53,873,187 \$ (541,590,242) \$ 27 1,712,257,751 \$ \$842,54 1,816,642 1,816,642 27 27 27 27 27 27 27 27 27 2	1700 5,915,21072 \$ 69,152,167	25% 7,727,046,397 8 38,635,227 8 (1.195,917,503) \$ (1.195,917,503) \$ 29 1,700,212,480 \$ 51,050,212,480 \$ 51,050,212,480 \$ 51,700,212,480 \$ 51,700,212,480 \$ 51,700,212,480 \$ 51,700,212,480 \$ 29 29 29 4,516,007 \$ 51,333,59	30 9,946,226,679 9,946,226,679 (1,517,469,929) 1,826,368,919 1,826,368,919 31,624,368,919 30 \$1,023,835,987 1,023,835,987 1,023,835,987 30 802,632,932 \$1,826,926 \$1,826 \$1,826,926 \$1	TOTAL \$8,973,773 TOTAL 4,524,428 4,049,347
ET VARIANCE umulative Target Limit umulative Target Erroratase (CTP) umulative Target Percentase (CTP) umulative Displayer Neutraliv Limit (CR) lowed Cumulative Variance (*CTP X CRNL) chauta. Constitution Positive of Oversondrian a Corrective Action Plan needed? PPOTHETICALS TEST 1 Ittho. Walver Total Expenditures VPOTHETICALS VARIANCE 1 VPOTHETICALS VARIANCE 1 VPOTHETICALS TEST 2 Itthout-Walver Total Expenditures Vpothetical 2 Per Capita a - CSS a - CSS TAL.	1	PMPM Mem-Mon Total PMPM	\$	26 1,696,397,398 \$ 33,727,347 \$ (249,596,995) \$ 26 1,290,056,737 \$ 6993,27 1,411,053 21,269,056,737 \$ 5093,27 1,411,053 21,269,056,737 \$ 26 5042,893,100 \$ 642,893,100 \$ 642,893,100 \$ 642,810,10	15% 3.591545775 \$ 53.673.197 \$ (5541590.2421 \$ 27 1,712,257,751 \$ 5342,54 1,712,257,751 27 27 27 27 27 27 27 27 27 2	1700 5,915,21072 \$ 69,152,167	0.5% 7.727,045.397 \$ 7.727,045.397 \$ 836,835.227 \$ (1.196.917.503) \$ 1.700,212,480 \$ 51,035.20 1,442.400 51,700,212,480 55,514,864 853,114,864 853,114,864 853,114,864 853,114,864 853,114,864 853,114,864 853,114,864	39 9,946,226,679 9,946,226,679 (1.517,469,929) 1,826,368,919 \$1,064,89 \$1,064,89 \$1,064,99 \$1,064,99 \$1,064,99 \$1,063,460 \$1,826,368,919 1,023,835,987 \$802,532,932 \$3 \$4,073	TOTAL \$8,973,773 TOTAL 4,524,428 4,049,347
ET VARIANCE umulative Target Limit umulative Target Everoritace (CTP) umulative Total Everoritace (CTP) umulative Disclere Neutrality Limit (CRNL) lowed Cumulative Variance (*CTP X CRNL) duals Camulative Variance (*CTP X CRNL) a Corrective Action Plan needed? YPOTHETICALS TEST 1 lithout-Waiver Total Expenditures ypothetical 1 Per Capits OTAL THIS WAIVER TOTAL STEED STEED STEED STEED STEED TOTAL YPOTHETICALS VARIANCE 1 YPOTHETICALS VARIANCE 1 YPOTHETICALS VARIANCE 1 YPOTHETICALS TEST 2 Ithhout-Waiver Total Expenditures YPOTHETICALS TEST 2 Ithhout-Waiver Total Expenditures OTAL TOTAL	1	PMPM Mem-Mon Total PMPM	\$	26 1,696,397,398 \$ 33,727,347 \$ (249,596,995) \$ 26 1,290,056,737 \$ 6993,27 1,411,053 21,269,056,737 \$ 5093,27 1,411,053 21,269,056,737 \$ 26 5042,893,100 \$ 642,893,100 \$ 642,893,100 \$ 642,810,10	15% 3.591545775 \$ 53.673.197 \$ (5541590.2421 \$ 27 1,712,257,751 \$ 5342,54 1,712,257,751 27 27 27 27 27 27 27 27 27 2	1700 5,915,21072 \$ 69,152,167	0.5% 7.727,045.397 \$ 7.727,045.397 \$ 836,835.227 \$ (1.196.917.503) \$ 1.700,212,480 \$ 51,035.20 1,442.400 51,700,212,480 55,514,864 853,114,864 853,114,864 853,114,864 853,114,864 853,114,864 853,114,864 853,114,864	39 9,946,226,679 9,946,226,679 (1.517,469,929) 1,826,368,919 \$1,064,89 \$1,064,89 \$1,064,99 \$1,064,99 \$1,064,99 \$1,063,460 \$1,826,368,919 1,023,835,987 \$802,532,932 \$3 \$4,073	TOTAL \$8,973,773 TOTAL 4,524,428 4,049,347
ET VARIANCE umulative Target Limit umulative Target Percentage (CTP) umulative Targ	1	PMPM Mem-Mon Total PMPM	\$	2.6% 2.7% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6	15% 3.691546.757 8 53.673.167 8 53.673.167 8 (5541.590.242) \$ 1.172.257.751 \$ 5342.54 1,816.642 31,912.257,751 27 27 27 27 5873,642.680 \$ 533.642.680 \$ 533.642.680 \$ 533.642.680 \$ 533.642.680 \$ 533.643.697 \$	1708 5,615,216722 \$ 56,152,1672 \$ 56,152,167 \$ 6867,679,861) \$ 28 2,056,675,689 \$ 5867,77 2,091,433 2,065,675,689 1,030,749,731 1,030,749,731 5,1030,749,731 28 28 51,301,23 5	0.5% 7,727,045,097 8 7,727,045,097 8 36,635,227 \$ (1.195,917,503) \$ 29 1,700,212,480 \$ 51,035,20 1,642,400 \$ 15,035,20 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 1,642,400 \$ 15,035,20 \$	30 9.946.226.679 9.946.226.679 1.826.368.919 1.826.368.919 1.826.368.919 30 51.826.368.919 30 51.826.368.919 30 51.623.835.987 1.623.835.987 5.820.928 5.423.95 4.073 5.820.928 5.820.928 5.820.928 5.820.928 5.820.928	TOTAL \$8,673,773 TOTAL 4,524,426 4,049,347
ET VARIANCE mulative Target Eventace (CTP) mulative Target Percentace (CTP) mulative Target Percentace (CTP) mulative Target Percentace (CTP) mulative Target Percentace (CTP) mulative Variance (* CTP X CBNL) tata Carmelative Variance (* CTP X CBNL) tata Carmelative Variance (* CTP X CBNL) tata Carmelative Variance (* Post Variance (* CTP X CBNL) tata Carmelative Variance (* Post Variance (* CTP X CBNL) tata Carmelative Variance (* Post Variance (* Po	1	PMPM Mem-Mon Total PMPM	\$ \$ \$	2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6%	15% 3,591,545,775 5,3673,679 3,591,545,775 1,712,557,751 27 27 2873,842,580 573,842,580 573,842,680	1,0% 5,615,210,727 2,8 5,615,210,727 2,8 5,615,210,727 2,615,210,73 2,867,879,861) \$ 28 2,066,875,689 2,061,433 2,065,875,689 28 \$1,030,749,731 1,030,749,731 1,030,749,731 2,011,730,749,741 2,011,730,749,741 2,011,730,749,741 2,011,730,749,741 2,011,730,749,741 2,011,730,749,741 2,011,730,741 2,011	0.5% 7.727,045.397 \$ 7.727,045.397 \$ 8.8,635.227 \$ (1.196.917.503) \$ 1.700,212.480 \$ 51,035.20 1,44.60 \$ 51,700,212.480 \$ 51,700,212.480 \$ 953,114.864 \$ 747,097,616 \$ 4.516.087 \$ 51,335.90 3,312 \$ 4.516.087 \$ 4.516.087 \$	30 9,946,226,679 9,946,226,679 1,517,469,929) 1,626,358,919 1,624,569 1,623,369,919 30 51,625,368,919 30 51,625,368,919 30 802,632,932 5,820,928 51,429,15 4,073 5,820,928 51,429,15 4,073	TOTAL \$8,673,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337
TYANANCE mulative Target Devocatace (CTP) mulative Target Percentace (CTP) mulative Target Percentace (CTP) mulative Target Percentace (CTP) mulative Devocation (CTP) mulative State Percentace (CTP) mulative State S	1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$	1,696,977,087 \$ 33,727,347 \$ 1249,595,995) \$ 26 1,269,058,737 \$ 5899,37 1,411,053 51,269,058,737 \$ 5642,883,100 642,883,100 642,883,100 5 51,184,76 \$ 26 - \$ - \$	15% 3,591,546.778 \$ 53,873,187 \$ (541,590,242) \$ 27 1,712,257,751 \$ 5842,54 1,310,642 1,712,297,751 27 27 27 27 27 27 27 27 27 2	1700 5,915,21072 \$ 56,152,167 \$ 66,152,167 \$ 66,152,167 \$ 66,152,167 \$ 687,878,861 \$ \$ 286,878,788,61 \$ \$ 286,878,788,61 \$ 1,000,749,731 \$ 1,030,749,749,749,749,749,749,749,749,749,749	7,727,045,037 \$ 7,727,045,037 \$ 38,635,227 \$ (1.195,917,503) \$ 29	30 9,946,226,679 9,946,226,679 1,1,517,469,929) 1,1,623,368,919 1,1,623,460 1,1,623,460 1,1,623,460 1,1,623,460 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,463,470 1,1,623,470 1,1,623,470	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL
The control of the									
ET VARIANCE umulative Target Limit umulative Target Enveratace (CTP) umulative Target Preventace (CTP) umulative Target Neutrality Limit (CRNL) lowed Cumulative Variance (**CTP X CRNL) tatus Cumulative Variance (**CTP X CRNL) tatus Cumulative Variance (**CTP X CRNL) tatus Cumulative Variance (**Politive **Oversoendino*) a Corredive Action Plan needed? YPOTHETICALS TEST 1 ithout Waiver Total Expenditures ypothetical 1 Per Capita 35 - Crosp Vill 37AL THE VERY TOTAL EXPENDITURES TARL YPOTHETICALS VARIANCE 1 YPOTHETICALS VARIANCE 1 10 - CIS 37AL Ith Waiver Total Expenditures ypothetical 2 Per Capita 3 - CIS 4 - CIS	1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$	1,696,977,087 \$ 33,727,347 \$ 1249,595,995) \$ 26 1,269,058,737 \$ 5899,37 1,411,053 51,269,058,737 \$ 5642,883,100 642,883,100 642,883,100 5 51,184,76 \$ 26 - \$ - \$	15% 3,591,546.778 \$ 53,873,187 \$ (541,590,242) \$ 27 1,712,257,751 \$ 5842,54 1,310,642 1,712,297,751 27 27 27 27 27 27 27 27 27 2	1700 5,915,21072 \$ 56,152,167 \$ 66,152,167 \$ 66,152,167 \$ 66,152,167 \$ 687,878,861 \$ \$ 286,878,788,61 \$ \$ 286,878,788,61 \$ 1,000,749,731 \$ 1,030,749,749,749,749,749,749,749,749,749,749	7,727,045,037 \$ 7,727,045,037 \$ 38,635,227 \$ (1.195,917,503) \$ 29	30 9,946,226,679 9,946,226,679 1,1,517,469,929) 1,1,623,368,919 1,1,623,460 1,1,623,460 1,1,623,460 1,1,623,460 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,463,470 1,1,623,470 1,1,623,470	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL
ET VARIANCE unudative Target Limit unudative Target Experiment (CTP) unudative Target Preventage (CTP) unudative Disperative Neutraliv Limit (CDNL) lowed Cumulative Variance (c TCP X CDNL) chaute. Commission of Control of Con	1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$	1,696,977,087 \$ 33,727,347 \$ 1249,595,995) \$ 26 1,269,058,737 \$ 5899,37 1,411,053 51,269,058,737 \$ 5642,883,100 642,883,100 642,883,100 5 51,184,76 \$ 26 - \$ - \$	15% 3,591,546.778 \$ 53,873,187 \$ (541,590,242) \$ 27 1,712,257,751 \$ 5842,54 1,310,642 1,712,297,751 27 27 27 27 27 27 27 27 27 2	1700 5,915,21072 \$ 56,152,167 \$ 66,152,167 \$ 66,152,167 \$ 66,152,167 \$ 687,878,861 \$ \$ 286,878,788,61 \$ \$ 286,878,788,61 \$ 1,000,749,731 \$ 1,030,749,749,749,749,749,749,749,749,749,749	7,727,045,037 \$ 7,727,045,037 \$ 38,635,227 \$ (1.195,917,503) \$ 29	30 9,946,226,679 9,946,226,679 1,1,517,469,929) 1,1,623,368,919 1,1,623,460 1,1,623,460 1,1,623,460 1,1,623,460 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,987 1,1,623,463,463,470 1,1,623,470 1,1,623,470	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL
ET VARIANCE umulative Target Limit umulative Target Erroratace (CTP) umulative Target Percentace (CTP) umulative Buscher Neutraliv Limit (CRNL) liced Cumulative Variance (* CTP X CRNL) chause Company (* CRNL) chause Company (* CRNL) chause Company (* CRNL) chause Company (* CRNL) protection of the Company (* CRNL) TOTAL TITLE VARIANCE 1 VPOTHETICALS TEST 2 TITLE VARIANCE 1 VPOTHETICALS TEST 2 TITLE VARIANCE 1 VPOTHETICALS TEST 2 TITLE VARIANCE 1 VPOTHETICALS Per Capita G + CSS OTAL TITLE VARIANCE 2 VPOTHETICALS Per Capita G + CSS OTAL VPOTHETICALS VARIANCE 2 VPOTHETICALS VARIANCE 2 VPOTHETICALS VARIANCE 2	1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$	2.6% 2.7% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6	15% 3.591545.73 8 53.673.187 8 53.673.187 8 (541.590.242) \$ 1.712.257.751 \$ 5042.54 1,816.642 51,712.257.751 5873,642.680 \$ 5873,642.680 \$ 538.415.071 \$ 27 27 27 27 27 5 1,241.65 - \$ 51,241.65 - \$ 51,241.	10% 5,615,2167.278 5,615,2167.278 56,152,167.28 6867,679.8611 \$ 28 2,056,675,689 5867,78 2,091,433 22,056,675,689 1,030,749,731 1,030,749,731 28 51,030,749,731 28 28 28 51,030,749,731 28 51,030,749,731 51,030,749,749,749 51,030,749,749 51,030,749,749 51,030,749,749 51,030,749,749 51,030,749,749 51,030,749,749 51,030,749,749 51,030,749,749 51,030,749 51,03	0.5% 7.727,045,037 8.635,227 9.(1.195,917,503) 8 1.700,212,480 9.11,700,21	30 9,946,226,679 9,946,226,679 1,826,386,919 1,826,386,919 1,823,480 1,823,480 1,823,480 1,823,480 1,823,480 1,823,480 1,823,480 1,823,480 1,823,480 1,823,480 1,823,480 1,823,880 1,	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL 10,057
ET VARIANCE umulative Target Limit umulative Target Limit umulative Target Limit (CRN.) libored Cumulative Variance (* CTP) umulative Busper Neutrality Limit (CRN.) libored Cumulative Variance (* CTP X CRN.) claud. Consider (* CTP X C	1	PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6%	15% 3.691.562.775 5.3673.672 (541.590.242) \$ 27 1.712.257.751 \$ 5.942.54 1.816.642 51,712.257,751 \$ \$73,842.660	1 (7%) 5,615,2167,775 5,615,2167,775 561,152,167 5,615,2167,775 561,152,167 5,615,2167	0.5% 7.727.045.397 \$ 7.727.045.397 \$ 8.8,535.227 \$ (1.195.917.503) \$ 1.700,772.480 \$ 1.700,772.480 \$ 1.642.400 51,700,212.480 51,700,212.480 51,700,212.480 51,700,212.480 29 4.516.087 \$ 51,303.69 29 4.516.087 \$ 51,303.69 29 4.519.087 \$ 1.22,443 \$	30 9,946,226,679 9,946,226,679 1,626,368,919 1,626,368,919 1,626,368,919 30 51,626,368,919 30 51,626,368,919 30 51,626,368,919 30 5,626,326,322 \$ 30 5,626,326 30 5,663,970 \$ 5,663,970 \$ 196,958 \$	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL 10,057
ET VARIANCE umulative Target Limit umulative Target Limit umulative Target Limit (CRN.) libored Cumulative Variance (* CTP) umulative Busper Neutrality Limit (CRN.) libored Cumulative Variance (* CTP X CRN.) claud. Consider (* CTP X C	1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6%	15% 3.591545778 \$ 53.673.187 \$ (5541590.242) \$ 27 1.112,257.751 \$ 5042,54 1,816,642 1,816,642 1,816,642 1,816,642 27 27 27 27 27 27 27 27 27 2	1705 5,612;16722 \$ 5,612;16722 \$ 56,152;167 \$ 68,7873,861 \$ 28 2,056,875,889 \$ 5887,78 2,091,433 2,365,875,889 1,030,749,731 \$ 1,030,749,731 \$ 51,030,749,740,740,740,740,740,740,740,740,740,740	0.5% 7.727,045.397 \$ 7.727,045.397 \$ 8.8,535,227 \$ (1.195,917,503) \$ 1.700,212,480 \$ 51,035,20 \$ 1,642,400 \$ 51,700,212,480 \$ 51,700,212,480 \$ 51,700,212,480 \$ 29 4,510,087 \$ 51,335,80 \$ 3,312 4,516,087 \$ 29 4,393,944 \$ 122,145 \$ 123,165,855 \$ 53,719,15 \$	30 9,946,226,679 9,946,226,679 1,251,7469,929) 1,252,328,949	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL 10,057
ET VARIANCE umulative Target Limit umulative Target Percentage (CTP) umulative Target Percentage (CTP) umulative Target Percentage (CTP) umulative Target Percentage (CTP) umulative Variance (**CTP X CBNL) tack Cardialve Variance (**CTP X CBNL) a Corrective Action Plan needed? **YPOTHETICALS TEST 1 Ithout-Waiver Total Expenditures **ypothetical 1 Per Capita 35 - Group VIII **TALL** **YPOTHETICALS VARIANCE 1 **YPOTHETICALS VARIANCE 1 **YPOTHETICALS TEST 2 Ithout Waiver Total Expenditures **ypothetical 2 Per Capita 36 - CIS **TALL** **ITHOUT TOTAL S TEST 2 Ithout Waiver Total Expenditures **ypothetical 2 Per Capita 36 - CIS **TALL** **TALL** **YPOTHETICALS VARIANCE 2 **YPOTHETICALS VARIANCE 3 **YPOTHETICALS VARIANC	1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6%	15% 3.591545778 \$ 53.673.187 \$ (5541590.242) \$ 27 1.112,257.751 \$ 5042,54 1,816,642 1,816,642 1,816,642 1,816,642 27 27 27 27 27 27 27 27 27 2	1705 5,612;16722 \$ 5,612;16722 \$ 56,152;167 \$ 68,7873,861 \$ 28 2,056,875,889 \$ 5887,78 2,091,433 2,365,875,889 1,030,749,731 \$ 1,030,749,731 \$ 51,030,749,740,740,740,740,740,740,740,740,740,740	0.5% 7.727,045.397 \$ 7.727,045.397 \$ 8.8,535,227 \$ (1.195,917,503) \$ 1.700,212,480 \$ 51,035,20 \$ 1,642,400 \$ 51,700,212,480 \$ 51,700,212,480 \$ 51,700,212,480 \$ 29 4,510,087 \$ 51,335,80 \$ 3,312 4,516,087 \$ 29 4,393,944 \$ 122,145 \$ 123,165,855 \$ 53,719,15 \$	30 9,946,226,679 9,946,226,679 1,251,7469,929) 1,252,328,949	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL 10,057
March 1979 Mar									
ET VARIANCE umulative Target Limit umulative Target Limit umulative Target Percentage (CTP) umulative Target Neutraliv Limit (CBNL) lowed Cumulative Variance (**CTP) CBNL) lowed Cumulative Variance (**Polity Limit (CBNL) a Corrective Action Plan needed? **POPTHETICALS TEST 1 Itthout-Walver Total Expenditures Variance Variance Variance Variance	1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	265 1,269,056,737 \$ 1249,595,995) \$ 26 1,269,056,737 \$ 8899,37 1,411,053 1,269,056,737 \$ 869,37 1,411,053 \$ 51,269,056,737 \$ \$ 642,833,100 642,833,100 \$ 53,1184,76 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	15% 3.69154.5778 \$ 53.673.187 \$ (541.590.242) \$ 27 1.712.297.751 \$ 5342.54 1.816.842 1.816.842 541.712.297.751 \$ 573.442.680 \$ 573.442.680 \$ 573.442.680 \$ 27 27 27 28 - \$ 51.241.63 27 - \$ 53.366.27	1700 5,615,216722 \$ 56,152,1672 \$ 66,152,1672 \$ 66,152,167 \$ 687,873,8611 \$ 28 2,056,873,689 \$ 5867,778 2,061,433 32,065,875,689 \$1,030,749,731 1,030,749,731 1,030,749,731 28 28 28 28 28 51,030,123 5 51,030,125,969 5 28 28 51,030,125,969 5 51,030,125,969 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	7,727,045,097 \$ 7,727,045,097 \$ 38,635,227 \$ (1.195,917,503) \$ 29	30 9,946,226,679 9,946,226,679 1,1,517,469,929) 1,1,623,363,919 1,623,363,919 30 1,023,835,987 1,023,835,987 1,023,835,987 3,036,938 3,0	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL 10,057 279
ET VARIANCE umulative Target Limit umulative Target Erroratace (CTF) umulative Target Percentace (CTF) umulative Dispets (extrative Limit (CIRL) loosed Cumulative Variance (e CTP X CIRL) chance Committee (e CTP X CIRL) chance C	1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	26 1,696,397,398 \$ 33,727,347 \$ (249,596,995) \$ 26 1,299,056,737 \$ 699,377 \$ 699,377 \$ 699,377 \$ 699,377 \$ 699,377 \$ 699,377 \$ 699,377 \$ 699,377 \$ 699,377 \$ 699,377 \$ 691,379,479 \$ 691,379 \$ 691,	15% 3.691545775 \$ 53.673.197 \$ (541.590.2421 \$ 1.712.297.791 \$ 8042.94 \$ 1.712.297.791 \$ 8042.95 \$ 1.910.492 \$ 1.712.297.791 \$ 27 27 27 27 27 51.241.63 \$ 27 27 51.241.63 \$ 51.241.63 \$ 27 27 51.241.63 \$ 51.241.	1700 551524072 \$ 551524072 \$ 561524072 \$ 66152407 \$ 66152407 \$ 66878788611 \$ 28 2056875,689 \$ 509773 \$ 2,001,433 \$ 2,056,875,689 \$ 1,035,125,989 \$ 1,035,125,989 \$ 28 28 28 28 28 28 28 28 28 28 28 28 28	0.5% 7.727.045.397 \$ 7.727.045.397 \$ 8.8,535.227 \$ (1.195.917.503) \$ 1.702.712.480 \$ 1.702.712.480 \$ 1.702.712.480 1.702.712.480	30 9,946,226,679 9,946,226,679 9,946,226,679 1,526,388,919 1,526,388,919 30 51,626,388,919 30 51,623,363,5897 1,623,363,5897 1,623,363,5897 30 5,620,928 51,429,15 4,073 5,620,928 51,429,15 4,073 5,620,928 51,429,15 4,073 5,620,928 51,429,15 4,073 5,620,928 51,429,15 6,63,970 5,663,970	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,057 279 TOTAL
ET VARIANCE umulative Target Limit umulative Target Everoritace (CTP) umulative Target Preventace (CTP) umulative Disperse Neutraliv Limit (CRNL) lowed Cumulative Variance (*CTP) X CRNL) towed Cumulative Variance (*CTP X CRNL) dual Cumulative Variance (*CTP X CRNL) a Corrective Action Plan needed? YPOTHETICALS TEST 1 lithout-Waiver Total Expenditures ypothetical 1 Per Capits 05 - Group VIII DTAL THIN Waiver Total Expenditures ypothetical 4 Per Capits 05 - Group VIII OTAL YPOTHETICALS VARIANGE 1 YPOTHETICALS VARIANGE 1 YPOTHETICALS TEST 2 IIIIhout-Waiver Total Expenditures ypothetical 2 Per Capits 06 - CIS OTAL IVENTIFICALS VARIANGE 2 YPOTHETICALS VARIANGE 2 YPOTHETICALS TEST 3 IIIIN Waiver Total Expenditures YPOTHETICALS TEST 3 IIIN Waiver Total Expenditures	1 1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	2.69.058.737 \$ 26.09.058.737 \$ 1.269.058.737 \$ 1.269.058.737 \$ 1.269.058.737 \$ 1.411.053 \$ 26.09.058.737 \$ 26.	15% 3.69154.5778 \$ 53.673.187 \$ 53.673.187 \$ (541590.242) \$ 27 1.712.297.751 \$ \$8042.54 1.816.642 1.816.642 5 873.842.680 \$ 873.842.680 \$ 873.842.680 \$ 27 27 27 27 27 28 5 1.241.63 27 27 5 5.386.27 5 \$ 5 \$ 5 \$ 7 \$ 83.848.680 27 27 5 \$ 6 \$ 7 \$ 8 \$ 8 \$ 8 \$ 8 \$ 8 \$ 8 \$ 8	28 28 2005,875,689 28 2005,875,689 28 2005,875,689 28 1005,875,689 28 1005,875,689 28 28 2005,875,689 28 28 28 28 28 28 28 28 28	0.5% 7.727,045.397 \$ 7.727,045.397 \$ 8.86,35,227 \$ (1.195,917,503) \$ 1.700,212,480 \$ \$1,005,20 \$ 1,602,480 \$ \$1,005,20 \$ 1,602,480 \$ \$1,606,480 \$ \$1,606,480 \$ \$29 4,516,087 \$ \$3,312 4,516,087 \$ 29 4,516,087 \$ 3,312 29 4,393,944 \$ 122,143 \$ 123,16,585 \$	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	TOTAL \$8,573,773 TOTAL 4,524,426 4,049,347 TOTAL 10,337 TOTAL 10,057 279
ET VARIANCE umulative Target Limit umulative Target Erroretage (CTF) umulative Bused Percentage (CTF) umulative Bused Horizon (CTF) umulative Bused Horizon (CTF) umulative Bused Horizon (CTF) umulative Variance (*CTP X CBNL) ducate Cardiale (*CTP X CBNL) ducate Car	1 1	PMPM Mem-Mon Total PMPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6%	15% 3.69154.5778 \$ 53.873.187 \$ (541.590.242) \$ 27 1.712.257.751 \$ 5042.54 1.816.642	1700 5,615,216722 \$ 56,152,1672 \$ 66,152,1672 \$ 66,152,167 \$ 687,873,8611 \$ 28 2,056,873,689 \$ 587,778,8611 \$ 2,061,433 \$ 2,064,433 \$ 2,	7,727,045,037 \$ 7,727,045,037 \$ 38,635,227 \$ (1.195,917,503) \$ 29	30 9,946,226,679 9,946,226,679 1,826,368,919 1,826,368,919 1,826,368,919 30 1,826,368,919 1,923,835,987 1,923,835,	TOTAL \$8,573,77: TOTAL 4,524,424 4,049,34: TOTAL 10,05: 27: TOTAL 28,19: TOTAL

PRA Disclosure Statement

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is **0938-1148 (CMS-10398 #56)**. The time required to complete this information collection is estimated to average **7.5 hours** per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

Budget neutrality is a Federal policy that governs the Federal expenditures for 1115 demonstrations. It is assured by placing an upper limit on the amount of Federal Financial Participation (FFP) the state can receive during the demonstration. The upper limit represents what the state could have received in the absence of the 1115 demonstration.

The Budget Neutrality workbook will assist in collecting standardized data in order to determine financial performance for the demonstration in terms of budget neutrality.

The workbook has two major groups of tabs: the first group collects and calculates Without Waiver (WOW) numbers, and the second group calculates With Waiver (WW) numbers. Data is collected per each demonstration Medicaid Eligibility Group (MEG), by demonstration year (DY). A Medicaid section 1115 demonstration is considered budget neutral if the Federal title XIX match, or funding received by the state (i.e., "with waiver" expenditures) do not exceed what the state would have (or could have) received without the demonstration (i.e., "without waiver" expenditures). The workbook provides the ability to evaluate any variance between WW and WOW calculations.

The workbook consists of 15 tabs which contain different types of data and calculations. The following color schema is applied to the tabs:

Blue	Information populated in the Budget Neutrality workbook template based on the demonstration's approved STC
Red	Information populated by states on a quarterly basis or per the reporting requirements defined in the STC
Gree	Information automatically populated based on the input from other worksheets

Note: Overview and Dropdowns tabs are read-only, no data entry is required. The Dropdowns tab displays the values used to build the dropdowns menus thoroughout the workbook, including the list of active waivers for the demonstration.

Within the tabs where a State User populates information (C Report, Total Adjustments, WW Spending Projected, MemMon Actual, MemMon Projected, and Summary TC Data Entry tabs), yellow highlighted cells denote where data entry may be needed (depending on DY being updated).

Pre-populated values in the downloaded Budget Neutrality workbook template

The original workbook entries are based on the STCs and other demonstration approval documentation. These entries are made on the DY Def, MEG Def, WOW PMPM & Agg, Program Spending Limits, and Summary TC tab (Phase-Down Percentage and Cumulative Target Percentage fields).

The MEG Def tab defines MEGs as Medicaid populations (core demonstration populations), Hypothetical populations (when a demonstration has separate budget neutrality agreements) and Tracking Only populations (for example, "pass-through" populations). The MEG Def tab also defines how expenditure numbers are calculated for a MEG (Per Capita vs. Aggregate) and the applicable scenarios (WOW, WW, or both). Also, the tab contains indicators defining MEG characteristics such as expenditure caps or applicability of savings phase-down calculations.

Calculating With Waiver (WW) numbers

WW numbers for each active DY of a demonstration are calculated based on a combination of actual WW expenditures, projected future expenditures, and any adjustments entered by a State User. The actual WW expenditures are copied from the Schedule C of the MBES CMS-64 report to the workbook (C Report tab). These numbers are automatically transferred to the C Report Grouper tab, where waiver expenditures are grouped by MEGs. The numbers are also transferred to the WW Spending Actual tab, which factors in adjustments entered on the Total Adjustments tab to calculate total actual WW expenditures. The WW Spending Total tab displays the actual WW expenditures plus future projected expenditures (transferred from the WW Spending Projected tab). Finally, the total WW actual and projected numbers are transferred to the Summary TC (Total Computable) tab (into the With-Waiver Total Expenditures section).

Calculating Without Waiver (WOW) numbers

WOW numbers can be obtained either one of two ways: using Aggregate or Per Capita calculations. If total projected expenditures for a MEG is known and the expenditure calculation type is defined as 'Aggregate' on the MEG Def tab, the total projected expenditure amount is entered for each active DY. However, if the expenditure calculation type is defined as 'Per Capita', total projected expenditures are derived by multiplying per member per month (PMPM) costs by the actual number of member months.

Both Aggregate and PMPM numbers are populated on the WOW PMPM & Agg tab. The number of actual member months (number of beneficiaries times the number of months enrolled) are entered by a State User on the MemMon Actual tab for each DY. On the MemMon Projected tab, State User enters projected numbers. The totals for actual and projected member months are calculated on the MemMon Total tab. WOW aggregate, PMPM and member month data is then moved to the the Without-Waiver Total Expenditures section of the Summary TC tab, where final calculations are performed.

Based on information from all tabs, the WW and WOW numbers are compared to determine the budget neutrality status of the demonstration.

Below are the definitions for the tabs of the workbook which require data entries from State User.

On top of the C Report tab, enter data in the following highlighted cells:

'Data Pulled On:' - enter the date the source file used to enter data on this tab was pulled

'For the Time Period Through :' - enter the date through which the source file data was pulled

Reporting DY' - enter the Demonstration Year (DY) for which data is being reported. Entered DY value must align with DYs from the DY Def tab.

Reporting Quarter' - enter a number of the quarter (values 1 through 4) for which data is being reported.

Notes:

- Dates must be entered in the following format: mm/dd/yyyy
- Reporting DY and Reporting Quarter entries affect which portion of the 'Medicaid Aggregate' and 'Medicaid Aggregate WOW only' amounts for a DY will be calculated as Actuals, and which will be calculated as Projected
- Entry for each of these four fields is required for the workbook submission. If any field is not populated, you will receive an error and the document will not be uploaded to the system.

State User enters information on the following tabs:

C Report Tab

Open Schedule C of the CMS 64 Expenditure Report. Under your state, locate expenditure data for the specific demonstration.

From this location on the CMS 64 Expenditure Report, copy expenditure data cells for all DYs (active and non-active). On the C Report tab, paste the data into the correct cell/row. Repeat the copy and paste process for MAP Waivers section (Total Computable and Federal Share) and ADM Waivers section (if applicable). Verify that the pasted numbers are correctly aligned with the Waiver Name values.

Total Adjustments tab

When adjustments are relevant for a demonstration, enter the actual numbers of total contributions to the reported expenditures, per each MEG, for the reporting quarter. Add new reported adjustments to any existing numbers for previous quarters for the reported DY.

Note: Any adjustments that reduce expenditures must be entered as negative numbers (for example, -\$10,000).

WW Spending Projected tab

Enter projected annual expenditures for each MEG for the active DYs of a demonstration.

For each reporting quarter, update the projected numbers so they reflect only future quarter projections. Please see the example for the MemMon Projected tab.

MemMonth Actual tab

For each MEG, calculate the actual number of member months for the reported quarter and add this number to the previously entered number for the same DY. For example, for Q3 reporting period, add Q3 member months to the existing number for the same MEG and DY and enter the result into the same cell.

MemMonth Projected tab

For each MEG, enter projected (future) annual member months for all active DYs of the demonstration. Adjust future DY numbers as needed. For the current DY, enter only the number that reflects future quarters. For example, for Q3 reporting, only enter the projected number for Q4. There should be no projected numbers for completed (actual) DYs.

Summary TC tab

In the Net Variance section, for each DY, enter estimated numbers in row '1115A Dual Demonstration Savings (state preliminary estimate)'.

In the next row, '1115A Dual Demonstration Savings (OACT certified)' enter certified numbers.

Both estimated and certified numbers must be negative, as dual demonstration savings numbers reduce the Net Variance amount.

Damasatatian Varia Ballatian

Demonstration Years Definitions																														
DY	- 1	2	3	4	- 5	- 6	7	8		10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
Start Date	8/1/1994	8/1/1995	8/1/1996	8/1/1997	9/1/1998	9/1/1999	9/1/2000	9/1/2001	9/1/2002	9/1/2003	9/1/2004	9/1/2005	9/1/2006	9/1/2007	9/1/2008	9/1/2009	9/1/2010	9/1/2011	9/1/2012	10/1/2013	1/1/2014	1/1/2015	1/1/2016	1/1/2017	1/1/2018	8/1/2019	8/1/2020	8/1/2021	8/1/2022	8/1/2023
End Date	7/31/1995	7/31/1996	7/31/1997	7/31/1998	8/31/1999	8/31/2000	8/31/2001	8/31/2002	8/31/2003	8/31/2004	8/31/2005	8/31/2006	8/31/2007	8/31/2008	8/31/2009	8/31/2010	8/31/2011	8/31/2012	8/31/2013	12/31/2013	12/31/2014	12/31/2015	12/31/2016	12/31/2017	7/31/2019	7/31/2020	7/31/2021	7/31/2022	7/31/2023	7/31/2024

MEG Definitions

MEG Name	MEG Description	Savings Phase-Down	Expenditures Subject to Cap?	Hypothetical Populations Included in Calculations?	Start DY	Start Date	End DY	End [
Medicaid Per Capita								
EG 1 - Children		Savings Phase-Down	No	N/A	1	8/1/1994	25	7/31/2
EG 2 - Adults EG 3 - Aged		Savings Phase-Down Savings Phase-Down	No No	N/A N/A	1	8/1/1994 8/1/1994	25 25	
EG 4 – Blind/Disabled	Income up to and including 100% FPL using the institutional income	-			,	0/1/1994	25	1/31/
	rules, including the application of regular post-eligibility rules and spousal	Savings Phase-Down	No	N/A				
	impoverishment eligibility rules.			N/A	1	8/1/1994	25	7/31
Medicaid Per Capita - WOW only		N/A		N/A				
		N/A		N/A				
		N/A N/A		N/A N/A				
		N/A N/A		N/A N/A				
Medicaid Aggregate		N/A		N/A				
		N/A		N/A				
		N/A		N/A				
		N/A N/A		N/A N/A				
				1471				
Medicaid Aggregate - WOW only		N/A		N/A				
		N/A N/A		N/A N/A				
		N/A		N/A				
		N/A N/A		N/A N/A				
		19/75		IN/A				
Medicaid Aggregate - WW only								
		N/A N/A		N/A N/A				
		N/A		N/A				
		N/A		N/A				
		N/A		N/A				
Hypothetical 1 Per Capita				Hypothetical Test 1				
EG 5 – Group VIII	Adults eligible for Medicaid as the group defined in section	N/A	No	Yes	20	10/1/2013	20	12/3
	1902(a)(10)(A)(i)(VIII) of the Act	N/A		res	20	10/1/2013	20	12/3
		N/A						
Hypothetical 1 Aggregate								
Trypodietical i Aggregate		N/A						
		N/A						
		N/A						
Hypothetical 2 Per Capita				Hypothetical Test 2				
EG 6 - CIS	Expenditures related to the CIS benefits of pre-tenancy supports and	NI/A	N-					
	tenancy supports; excludes expenditures related to the Community Transition Services Pilot Program.	N/A	No	Yes	26	8/1/2019	30	7/3
		N/A				3.,,20.0	30	
		N/A						
Hypothetical 2 Aggregate								
		N/A						
		N/A N/A						
		1975						
Hypothetical 3 Per Capita				Hypothetical Test 3				
EG 7 – CIS Community Transition Pilot	Expenditures related to the Community Transition Services Pilot Program.	N/A	No	Yes	26	8/1/2019	30	7/31
	. rogram.	N/A			20	3/1/2013	30	1131
		N/A						
Hypothetical 3 Aggregate								
podieticai o Aggiegate		N/A						
		N/A N/A						
		IN/A						

WOW PMPMs and Aggregates

		26	27	28	29	30
Medicaid Per Capita EG 1 - Children EG 2 - Adults EG 3 - Aged EG 4 – Blind/Disabled	1 2 3 4	\$448.48 \$925.47 \$1,939.17 \$2,646.76	\$452.96 \$959.72 \$2,005.11 \$2,763.22	\$457.49 \$995.23 \$2,073.28 \$2,884.80	\$462.07 \$1,032.05 \$2,143.77 \$3,011.73	\$466.69 \$1,070.24 \$2,216.66 \$3,144.25
		26	27	28	29	30
Hypothetical 1 Per Capita EG 5 – Group VIII	1	\$899.37	\$942.54	\$987.78	\$1,035.20	\$1,084.89
		26	27	28	29	30
Hypothetical 2 Per Capita EG 6 - C/S	1	\$1,184.76	\$1,241.63	\$1,301.23	\$1,363.69	\$1,429.15
		26	27	28	29	30
Hypothetical 3 Per Capita EG 7 – CIS Community Transition Pilot	1	\$3,231.17	\$3,386.27	\$3,548.81	\$3,719.15	\$3,897.67

Program Spending Limits

						TOTAL
Program Name and Associated MEGs	26	27	28	29	30	
Spending Cap						
						\$ -
Expenditures Subject to Cap						
Variance						\$ -
Over or Under						

il information related to the demonstrati	ition from Schedul+ C ~	the CMS #41	Valver Expervis	Per	the Time	ACCUSES.		day Over																				
ne Schedule C Report, Jocale ross rele- piate hao rounds of copylpasie stating- plate hao rounds of copylpasie stating- PP Walvers 7 lotal Computable section - AP Walvers 7 lotal Computable section - In M walvers are applicable to The demons cost in column A (Walver Name). DM Walvers 1 Total Computable section - C DM Walvers 1 Total Computable section - C DM Walvers 1 Federal Share section - C	event to all expenditure g from the cell in column n – into cell A100 into cell A200 natration, complete two	for a specific A (Walver Na	demonstration. me).																									
MAP Walvers																												
moutable																												
Walter Name		62	- 63	- 04	46	- 06	67	- 00	-	10		- 13		**	16	- 17	- 19	**	30	21	22 22	- 34 -	36	ж.	- 27	26	76	30 To
on our services of the control of th	10,00,00 10,00 10,00					(44,446)					: :										: :							100,000 100,000 100,000 100,000 100,000 100,000
	0 00,000 0 00,000										: :										: :							:
	: :										: :		100	0.000	10,000,000	00,00,00	Market and the second	0,00,00	14,000,000		(m) (m) (m)	10,000,000	0.1000	MAJANA, MAY	-	Marian Maria	0.78(40	
unit	- : :	- :	- :	- :	- :	- :					: :		- :		- :							(00,000)	10.00	(91,00)		- :		1,70,00
	- : :	- :	- :	- :	- :	- :					: :		(40,000)	10,700,000 10,700,000	10,700,000	10,000,000 100,000,000	PORTOR .	m,m,m			On House	90,000,000 90,000,000	10,14,44	MATERIAL SECTION SECTI	101, 101, 101 101, 101, 101	100,000,000 100,000,000	0,00,00	
Makeus MY	- : :	- :		- :	- :	- :	- :	- :			: :	- :	- :	- 1	- :		- :		-			100,000,000 10,000,000 (00,000,000 (00,000,000 (00,000,0	10,100 mm	MARIANA PAR MARIANA PAR MARIAN	200	- :		0 0000 0 00000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 00000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 00000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 0000 0 00000 0 0000 0 00000 0 0000 0 00
Teamer (MET)		- :		- :	- :	1,000,000	*******	70,000,000			: :	- :	- :			14,00		740,000		10,000		-	10,00	4,000		11,000		
							- :	4000		:	: :										: :							
	: :						- :			10,000		10,00,00	***************************************	170,000,000		AM(100, 110)		10,00	175,000	NAME OF THE PARTY		100,000,000	******	1/10/100	70,00,00 000,00	000,000,000 1,700,000	00,70,00	1,000
,		100,000	0,800,000	1,000,000	***	1,740,000		- :	-		: :			0,00 0,00 00,00	1,00		10,000		170,000		-			(700,000		(40,00		: 3
	1,00,00	1000	10,000,000		10000		1000				0,00,00		100,000	14,00	- :		- :				: :	- :				- :	- :	1,000
						1,000					90,000	10,00	100,000	100	110.00		4.40	- 1	- 1			- 1	- :	- 1	- :	- 1	- 1	
		- 1	- 1	- 1	- 1	- 1	- 1	- 1	- 1		: :	- 1		10,110	-	- 1	- 1	- 1								17111111		
	- : :	- 1	- 1	- 1	- 1							-	1,000,000	10,000,007								-						
	40,000	- 1	- 1	- 1	- 1	780,000	10,000,700	10,000,000 10,000,000	- 1			-			-	- 3	- 1	- 1	- 1			- 1	- 1	- 1	- 1	- 1		10,00
	(0,00,00)	- 1	- 1	- 1	- 1	- 1	- 1		- 1						-		-					- 1	- 1	- 1	- 1	- 1		
		- 1	- 1	- 1	- 1	- 1	- 1	- 1	- 1			-	1,000,000	10,000,000														0.0
		- 1	- 1	- 1	- 1	- 1	- 3		-			120,000,000	100,000 m	10,00,00		100,000	(100,00° (100,00°)	(25)00 10(10)07 10(10)07	100,000 100,000 100,000			0.000,000 000,000,000	00,000,000 00,000,000	0.000,000 00.000,000		0.000,000 0.000,000 0.000,000	4,44,44 2,13,44	
		- 1	- 1	- 1	- 1	- 1	3	7	-	1 000														-				
	1 1	- 1	- 1	- 1	- :	- 1	- :				0,000,00	41,000,000		10,700,000	an market			*****	tanoni.			- 1		- 1		- 1		
	4 1494494		10.070.100			14440.144	:_					1,81,74	Concess	10000	00000	100000	_:_	*****	10,000,000 10,000,000 10,000,000	10,740,000 Hotel	-	:		1114601781	:_		:	
hare																												-
Walver Name	A 01	02	03	04	05	06	67	08		10 1	1 12	- 13	14	15	16	17	18	19	20	21	22 2	24	25	26	27	28	29	20 To
	10,00,00 10,00 10,00 10,00					(64,666)					: :										: :							
	- 10,000 - 70,000,007		:						:	:	: :			:		:		:		:	: :		:		:			
	- : :	- :		- :		- :					: :		-	0,0000	10,000,000	10,00,00	100,000,000	10,00,00	1700,000		OR 1000000	100,000,000 100,000,000	0.00	10,700,000 10,000,000	10,000	70,000,000	10,000,000	1 100
and the same of th		- :				- :	- :			1	: :											(May And) and (May And) (May An	100,000,000 (100,000) (100,000) (100,000) (100,000) (100,000) (100,000) (100,000) (100,000)	AND THE PROPERTY OF THE PROPER				
	- : :	- :		- :		- :					: :		(11,00)	0,000	10,000,000 100,000,000	10,000,000	10,100,00°	0,00,00 10,00,00	10,000,000 10,000,000		(AR B)(AR)(AR	100,000,000	00,00,00	M(M), M1	10,000 10,000 10,000	10,100,000 (10,100,000	17,000 PM	
Marian MY	- : :	- :		- :		- :					: :				- :		- :			- 1	(40) (40)44	(44,44)	94.40	(40,00)		- :		- : :
Teacher (MIT)	440,000,000					900,000	E(14)16				: :				4,700		100,000			-		11,000	400	1,000	400			
		- :	:		:			10,000,000	:	:	: :			:		:					: :		:				:	4 May 2 May
	: :							10,000			7,00,00	70,700,007	M15000,000	110,100,000	100,000,000	PH, 84, 64	100,000,000	10,10,00	ACCUSATION .	A1944 MA194		***	70,10,00	47,000,000	MI (198,000	70,000,000	100,000,000	
	20,000	11,700	1,000,007		48/97				-		: :		10,000	9,00	1,00	***			*****			100,000	1,210,000	****	1,000,710	1,000,000		
	1,00,00	173,700	1,00,00	10000	1,000,000	1,000,000	1,000,007	10,000,000 10,000,000			0.000		10,000								: :							
		1000	100.00	CAROLIN .	CHICA	1,000,000	CHOIL	10,000,000			(m, m)	4.00				4,44	4,00	- :	- 1		: :	- :		- :		- :		
	- : :	- :		- :	- :	- :		- 1			: :			1,000			- 1	- :			: :			- :		- :		
		- :		- 1	- 1	- 1	- 1	- 1			:		4,000,000	-		- 3		- 1	-			10(10),00	14,140,140			-4,740,000	_,,,,,,	0 1,000,000 0 1,000,000 0 100,000 0 100,000 0 100,000 0 100,000 0 100,000 0 1,000,000
		- :		- 1	- 1		4000	10,000,000						-		- 1		- 1			1 1	- :	- 1	- 1	- 1	- 1	- 1	-
	-			- 1	- 1	- 1	- 1			-		:							:		1 1		- 1	- 1	- 1	- 1	- 1	-
	: :	- :	:					- :		:	1,44	****	4,000,000	1,110,100					10,000,000	4,400	: :		:					10,00
dene	: :	- :	:						-			10,000,000	10,000,000	10,000	MARKET AND ADDRESS OF THE PARTY AND ADDRESS OF	1,000,000 00,000,000 00,000,000	ALTERNATION TO SERVICE AND ADDRESS OF THE PERSON NAMED ADDRESS OF THE PERSON NAMED AND ADDRESS	1,00,000 10,100,000 10,000,000	MARKET I			1,000,000	0,000,000 000,000,000	1/0/00	1,00,00	100,000 100,000,000		1,000,00
or o	: :	- :	:					(0,000)		1 1000		10,70,00					11,100,000		MARKET I				W(70,00	44,44,46		*******	******	100
	- 1	- 1		- :	- :	- 1	- :	- 1	- :			4,44,46	10/10/100		10,000,000	4,44,41		1,000,000				- 1		- 1	- :	- 1	- :	
		:									1,41,44	1,000,000	4,000,000	100.00	100,00					100 mm		:	:					
-		*****	******	1411414	******		110 101 110	*********				107 250 242	WI PLAN			BET 244 344							1114441718	120 100 001				
ADM Walvers																			-	24							30	
ADM Walvers Walver Name	A 61	02	63	04	65	06	67	08	69	10	1 12	13	14	15	16	- 1/	_				4 1					- 4	- A	
ADM Walvers while Walver Name				*	- 65 :	- 06	67	- 08		10	0 73155	278 GV	14 10,000,000 40,000,407	15 1,18,41	16	9429411		E 201713		100			1393616	12 62 63	101074508	0.00001		8 129130

C Report Grouper

MAP Waivers Only

MEG Names		C Report Waiver Names					
			26	27	28	29	30
Medicaid Per Capita							
EG 1 - Children	1	FosterCare(19-20)	\$1,739,142	\$2,028,913	\$1,783,310	\$285,431	
EG 1 - Children	1	State Plan Children	\$391,865,047	\$420,400,786	\$428,058,364	\$72,971,905	
EG 2 - Adults	2	State Plan Adults	\$164,063,181	\$203,396,880	\$225,141,112	\$40,705,233	
EG 2 - Adults	2	Breast Cervical Cancer Treatment (BCCT)	\$6,122	\$35,680	\$11,676		
EG 2 - Adults	2	St PI Adults-Preg Immig/COFAs	\$3,127,056	\$2,106,507	\$1,646,061		
EG 3 - Aged	3	Aged w/Mcare	\$369,932,172	\$393,768,865	\$407,334,522	\$72,539,403	
EG 3 - Aged	3	Aged w/o Mcare	\$64,462,027	\$101,049,983	\$123,390,620	\$21,760,135	
EG 3 - Aged	3	Aged with Medicare - MFP	(\$490,186)	(\$31,916)			
EG 3 - Aged	3	Aged without Medicare - MFP	(\$17,253)				
EG 4 – Blind/Disabled	4	B/D w/Mcare	\$151,179,620	\$164,309,964	\$165,032,786	\$28,860,050	
EG 4 – Blind/Disabled	4	B/D w/o Mcare	\$330,668,845	\$365,118,586	\$363,014,834	\$61,525,813	
EG 4 – Blind/Disabled	4	Blind/Disable without Medicare - MFP	(\$294,330)	(\$17,997)			
EG 4 – Blind/Disabled	4	Blind/Disabled with Medicare - MFP	(\$81,788)	(\$2,258)			
Hypothetical 1 Per Capita							
EG 5 – Group VIII	1	VIII-Like Group					
EG 5 – Group VIII	1	Expansion State Adults	\$526,643,959	\$713,486,752	\$851,525,216	\$154,719,115	
EG 5 – Group VIII	1	Newly Eligible Adults	\$116,239,141	\$160,384,243	\$179,224,515	\$31,668,141	
Hypothetical 2 Per Capita							
EG 6 - CIS	1	EG 6 - CIS					
Hypothetical 3 Per Capita							
EG 7 – CIS Community Transition Pilot	1	EG 7 – CIS Community Transition Pilot					
TOTAL	!		\$2,119,042,755	\$2,526,034,988	\$2,746,163,016	\$485,035,226	

Adjustments made to the reported expenditures

Enter total adjustments made to the expenditure numbers, including adjustments to the previous reporting periods.

Positive adjustments increase expenditures, and negative adjustments decrease expenditures.

Enter adjustments for every MEG for which adjustments were made or are planned.

Helpful Hint: Remember to enter total adjustments as positive or negative (for example, -\$10,000 reflects a decrease in expenditures).

		26	27	28	29	30	Description (type of collection, time period, CMS-64 reporting line, etc.)
Medicaid Per Capita EG 1 - Children	1		-\$2,158				Cost share
EG 2 - Adults EG 3 - Aged EG 4 – Blind/Disabled	3	-\$35,830,002	-\$35,736,037	-\$34,461,395	-\$5,633,206		Cost share
Hypothetical 1 Per Capita	4	-\$3,558,280	-\$3,241,637	-\$3,570,563	-\$720,372		Cost share
EG 5 – Group VIII Hypothetical 2 Per Capita	1		-\$28,315				Cost share
EG 6 - CIS	1						
Hypothetical 3 Per Capita EG 7 – CIS Community Transition Pilot	1						

WW Spending - Actual

		26	27	28	29	30
<u>Medicaid Per Capita</u> EG 1 - Children EG 2 - Adults EG 3 - Aged	1 2 3	\$393,604,189 \$167,196,359 \$398,056,758	\$422,427,541 \$205,539,067 \$459,050,895	\$429,841,674 \$226,798,849 \$496,263,747	\$73,257,336 \$40,705,233 \$88,666,332	
EG 4 – Blind/Disabled Hypothetical 1 Per Capita EG 5 – Group VIII	1	\$477,914,067 \$642,883,100	\$526,166,658 \$873,842,680	\$524,477,057 \$1,030,749,731	\$89,665,491 \$186,387,256	
Hypothetical 2 Per Capita EG 6 - C/S	1					
Hypothetical 3 Per Capita EG 7 – CIS Community Transition Pilot TOTAL	1	\$ 2,079,654,472	\$ 2,487,026,841	\$ 2,708,131,058	\$ 478,681,648	\$ -

WW Spending - Projected

Enter projected spending for the demonstration which includes the remaining quarters of the current DY and all future DYs. Enter the projected annual expenditures for each DY per MEG for the active DYs.

For the current DY, only future quarters should have projected spending information. Do not include expenditures that were reported as actuals.

		26	27	28	29	30
Medicaid Per Capita						
EG 1 - Children	1				\$358,819,218	\$447,307,253
EG 2 - Adults	2				\$206,049,429	\$262,281,700
EG 3 - Aged	3				\$387,105,791	\$502,750,842
EG 4 – Blind/Disabled	4				\$559,522,203	\$685,289,061
Hypothetical 1 Per Capita						
EG 5 – Group VIII	1				\$766,727,608	\$1,023,835,987
Hypothetical 2 Per Capita						
EG 6 - CIS	1				\$4,393,944	\$5,663,970
Hypothetical 3 Per Capita						
EG 7 – CIS Community Transition Pilot	1				\$11,983,484	\$15,447,190

WW Spending - Total

- Cottan Companies						
		26	27	28	29	30
Medicaid Per Capita EG 1 - Children EG 2 - Adults	1 2	\$393,604,189 \$167,196,359	\$422,427,541 \$205,539,067	\$429,841,674 \$226,798,849	\$432,076,554 \$246,754,662	\$447,307,253 \$262,281,700
EG 3 - Aged EG 4 - Blind/Disabled	3 4	\$398,056,758 \$477,914,067	\$459,050,895 \$526,166,658	\$496,263,747 \$524,477,057	\$475,772,123 \$649,187,694	\$502,750,842 \$685,289,061
<u>Hypothetical 1 Per Capita</u> EG 5 – Group VIII	1	\$642,883,100	\$873,842,680	\$1,030,749,731	\$953,114,864	\$1,023,835,987
<u>Hypothetical 2 Per Capita</u> EG 6 - C/S	1				\$4,393,944	\$5,663,970
Hypothetical 3 Per Capita EG 7 – CIS Community Transition Pilot	1				\$11,983,484	\$15,447,190
TOTAL		\$ 2,079,654,472	\$ 2,487,026,841	\$ 2,708,131,058	\$ 2,773,283,325	\$ 2,942,576,003

Member Months - Actual

Enter actual member months (number of beneficiaries times the number of enrolled months) for quarters to date for each active DY.

For the reported quarter, add the actual number of member months per each MEG to the previous actual number. The number should equal the total of ALL actual member months.

Note: Depending of the specifics of the state, you can use Total member months or Average monthly unduplicated counts. Whichever definition is used, it must be applied consistently.

Helpful Hint: When updating a DY, remember to enter actual member months for the reported quarter along with actuals for prior quarter(s). Retroactive adjustments may affect the entries.

		26	27	28	29	30
Medicaid Per Capita						
EG 1 - Children	1	1403508	1539475	1624640	275495	
EG 2 - Adults	2	420665	492750	537079	91214	
EG 3 - Aged	3	339779	381363	426146	74440	
EG 4 – Blind/Disabled	4	286202	306260	312412	51890	
Hypothetical 1 Per Capita EG 5 - Group VIII	1	1411053	1816642	2091433	363654	
Hypothetical 2 Per Capita EG 6 - CIS	1					
Hypothetical 3 Per Capita EG 7 – CIS Community Transition Pilot	1					

Member Months - Projected

Enter/adjust projected member months based on reported actuals.

Enter projected number of member months for each active DY per MEG for the demonstration.

For the current DY, enter only the number that reflects projections for future quarters of the DY.

Do not include member months for either the current reporting quarter or past quarters.

		26	27	28	29	30
Medicaid Per Capita						
EG 1 - Children	1				1389509	1706629
EG 2 - Adults	2				449221	553945
EG 3 - Aged	3				265093	342929
EG 4 – Blind/Disabled	4				273822	328969
Hypothetical 1 Per Capita						
EG 5 – Group VIII	1				1278746	1683460
Hypothetical 2 Per Capita						
EG 6 - CIS	1				3312	4073
Hypothetical 3 Per Capita						
EG 7 – CIS Community Transition Pilot	1				3312	4073

Member Months - Total

		26	27	28	29	30
Medicaid Per Capita						
EG 1 - Children	1	1,403,508	1,539,475	1,624,640	1,665,004	1,706,629
EG 2 - Adults	2	420,665	492,750	537,079	540,435	553,945
EG 3 - Aged	3	339,779	381,363	426,146	339,533	342,929
EG 4 – Blind/Disabled	4	286,202	306,260	312,412	325,712	328,969
Hypothetical 1 Per Capita EG 5 – Group VIII	1	1,411,053	1,816,642	2,091,433	1,642,400	1,683,460
<u>Hypothetical 2 Per Capita</u> EG 6 - CIS	1				3,312	4,073
Hypothetical 3 Per Capita EG 7 – CIS Community Transition Pilot	1				3,312	4,073

The Budget Neutrality Reporting Period dropdown menu allows for selection of a specific reporting period, by Demonstration Year. By changing these settings, you change the view for which Demonstration Years will be used in calculating Budget Neutrality. Selecting the Reset to Delautis buttow will reset the Reporting DY values back to the demonstration carrier feel of Performance.

Budget Neutrality Reporting Start DY	26
Budget Neutrality Reporting End DY	30

reduality Reporting End D1	5
Actuals + Projected	

March Carlot Marc	Actuals + Projected	_								
Table Part	Without-Waiver Total Expenditures									Tetr'
10 10 10 10 10 10 10 10					26	27	28	29	30	Total
Description Property Company	Medicaid Per Capita EG 1 - Children	1		\$						
Part			PMPM Mem-Mon		\$448.48 1,403,508	\$452.96 1,539,475	\$457.49 1,624,640	\$462.07 1,665,004	\$466.69 1,706,629	
Part	EG 2 - Adults	2		\$						
			Mem-Mon		420,665	492,750	537,079	540,435	553,945	
1	EG 3 - Aged	3	PMPM	\$	\$1.939.17	\$2.005.11	\$2.073.28	\$2.143.77	\$2.216.66	
Part Column Col	EC 4 - RindDisshlad	4		ę						
	EG 4 - Billionsabled	-	PMPM	•	\$2.646.76	\$2.763.22	\$2.884.80	\$3.011.73	\$3.144.25	
Section Sect	TOTAL			\$						14,498,636,467
The state of the										
Color	Medicaid Des Capita				26	27	28	29	30	TOTAL
10	EG 1 - Children EG 2 - Adults			s s	167.196.359 \$					
State Procedure	EG 3 - Aged	3		\$	398,056,758 \$ 477,914,067 \$	459,050,895 \$	496,263,747 \$	475,772,123 \$	502,750,842	\$6,240,297,290
Secretary 1	TOTAL			\$	1,436,771,372 \$	1,613,184,161 \$	1,677,381,327 \$	1,803,791,033 \$	1,897,628,856	8,428,756,750
Microsoft Process 1	Savings Phase-Down	_								TOTAL
Windows	Medicald Per Capita		Savinos Phase-Down	-	26	27	28	29	30	TOTAL
Comparison Com	EG 1 - Children	1		\$	393,604,189 \$	422.427.541 \$	429,841,674 \$	432.076.554 S	447,307,253	
Comment Comm	Phase-Down Percentage			\$	25%	25%	25%	25%	25%	
Wide Name		2		\$						
Procedure Proc	Difference		With Waiver	\$	167,196,359 \$ 222,116,479 \$	205,539,067 \$ 267,362,963 \$	226,798,849 \$ 307,718,284 \$	246,754,662 \$ 311,001,279 \$	262,281,700 330,572,397	
With Name	Phase-Down Percentage		[25%	25%	25%	25%	25%	
Section Content	EG 3 - Aged	3		\$	658,889,243 \$					
Section Production			-viui waiver	s	260.832.486 \$	305.623.870 \$ 25%	387.256.232 \$	252.108.536 S	257.406.155	
March 1	Savings Reduction			\$	195,624,364 \$	229,217,903 \$	290,442,174 \$	189,081,402 \$	193,054,616	
Paper Pape		4		s s	477,914,067 \$	526,166,658 \$	524.477.057 \$	649,187,694 \$	685,289,061	
1 14,707,000 17,000,000 17,000,000 19,000,000	Phase-Down Percentage			\$	25%	25%	25%	25%	25%	
Anii		-		s						4.552.409.788
Company Comp										
1100 A Data Development Serving (Cold Transfer)	Excess Spending from Hypotheticals			\$	249,595,995 \$	291,994,247 \$	346,289,619 \$	308,037,642 \$	321,552,426	1,517,469,929
INTERPRETATION	1115A Dual Demonstration Savings (OACT certified)									:
Second S	NET VARIANCE		L	<u> </u>						1,517,469,929
	Cumulative Target Limit		1							
Consider food by More (Contain Contain Conta									30	
S	Cumulative Budget Neutrality Limit (CBNL)				2.0% 1.686.367.368 \$ 33.727.347 \$	1.5% 3.591.545.775 \$ 53.873.187 \$	1.0% 5.615.216.722 \$ 56.152.167 \$	7.727.045.397 \$ 38.635.227 \$	9.946.226.679	
### Without Water Total Expenditures 1				s					(1,517,469,929)	
### Part	is a Corrective Action Plan needed?									
### Part			1	-						
1 Total 5 1,000,000,737 5 1,712,297,761 5 2,000,000,737 5 1,712,297,761 5 2,000,000,737 5 1,712,297,761 5 2,000,000,731 1,710,217,400 1,000,000,919	HYPOTHETICALS TEST 1	l	l	1						
1		1		ı					1	
Mem-Mon	Without-Waiver Total Expenditures				26	27	28	29	30	TOTAL
Mith Walver Total Expenditures 26	Without-Waiver Total Expenditures Hypothetical 1 Per Capita	1		\$	1,269,058,737 \$	1,712,257,751 \$	2,065,875,689 \$	1,700,212,480 \$	1,826,368,919	TOTAL
28 27 28 29 20 TOTAL	Without-Waiver Total Expenditures Hypothetical 1 Per Capita	1	PMPM	\$	1,269,058,737 \$ \$899.37	1,712,257,751 \$ \$942.54	2,065,875,689 \$ \$987.78	1,700,212,480 \$ \$1,035.20	1,826,368,919 \$1,084.89	TOTAL
	Without-Waiver Total Expenditures Hypothetical 1 Per Capita ECS - Croup VIII TOTAL	1	PMPM	\$	1,269,058,737 \$ \$899.37 1,411,053	1,712,257,751 \$ \$942.54 1,816,642	2,065,875,689 \$ \$987.78 2,091,433	1,700,212,480 \$ \$1,035.20 1,642,400	1,826,368,919 \$1,084.89 1,683,460	
	Without-Waiver Total Expenditures Hypothetical 1 Per Capita ECS - Croup VIII TOTAL	1	PMPM	\$	1,269,058,737 \$ \$899.37 1,411,053 \$1,269,058,737	1,712,257,751 \$ \$942.54 1,816,642 \$1,712,257,751	2,065,875,689 \$ \$987.78 2,091,433 \$2,065,875,689	1,700,212,480 \$ \$1,035,20 1,642,400 \$1,700,212,480	1,826,368,919 \$1,084.89 1,683,460 \$1,826,368,919	\$8,573,773,575
### Without Waiver Total Expenditures #### Para	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Fer Capita		PMPM	\$	1,269,058,737 \$ \$899.37 1,411,053 \$1,269,058,737	1,712,257,751 \$ \$942.54 1,816,642 \$1,712,257,751	2,065,875,689 \$ \$987.78 2,091,433 \$2,065,875,689	1,700,212,480 \$ \$1,035,20 1,642,400 \$1,700,212,480	1,826,368,919 \$1,084.89 1,683,460 \$1,826,368,919	\$8,573,773,575
### Without Waiver Total Expenditures #### Para	Without-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII EG S - Group VIII		PMPM	\$	1,269,058,737 \$ \$899.37 1,411,053 \$1,269,058,737 26 \$642,883,100	1,712,257,751 \$ \$942.54 1,816,642 \$1,712,257,751 27 \$873,842,680	2,065,875,689 \$ \$987.78 2,091,433 \$2,065,875,689 28 \$1,030,749,731	1,700,212,480 \$ \$1,035,20	1,826,368,919 \$1,084,89 1,883,460 \$1,826,368,919 30 \$1,023,835,967	\$8,573,773,575 TOTAL
### State Part	Without-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII EG S - Group VIII		PMPM Mem-Mon	\$	1,269,058,737 \$ 8599.37 1,411,053 \$1,269,058,737 26 \$642,883,100 \$42,883,100 \$	1,712,257,751 \$ \$942.54 1,816,642 \$ 11,712,257,751 \$ 27 \$ 873,842,680 \$	2,065,875,689 \$ \$987.78 2,091,433 \$2,065,875,689 28 \$1,030,749,731 \$1,030,749,731 \$	1,700,212,480 \$ \$1,035,20 1,642,400 \$1,700,212,480 29 \$953,114,864 \$53,114,864 \$	1,826,368,919 \$1,084,89 1,883,460 \$1,826,368,919 30 \$1,023,835,967	\$8,573,773,575 TOTAL 5 4,524,426,362
Page 1	Without-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL HYPOTHETICAL S VARIANCE 1		PMPM Mem-Mon	\$	1,269,058,737 \$ 8599.37 1,411,053 \$1,269,058,737 26 \$642,883,100 \$42,883,100 \$	1,712,257,751 \$ \$942.54 1,816,642 \$ 11,712,257,751 \$ 27 \$ 873,842,680 \$	2,065,875,689 \$ \$987.78 2,091,433 \$2,065,875,689 28 \$1,030,749,731 \$1,030,749,731 \$	1,700,212,480 \$ \$1,035,20 1,642,400 \$1,700,212,480 29 \$953,114,864 \$53,114,864 \$	1,826,368,919 \$1,084,89 1,883,460 \$1,826,368,919 30 \$1,023,835,967	\$8,573,773,575 TOTAL 5 4,524,426,362
	Without-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1		PMPM Mem-Mon	\$	1,269,058,737 \$ 8599.37 1,411,053 \$1,269,058,737 26 \$642,883,100 \$42,883,100 \$	1,712,257,751 \$ \$942.54 1,816,642 \$ 11,712,257,751 \$ 27 \$ 873,842,680 \$	2,065,875,689 \$ \$987.78 2,091,433 \$2,065,875,689 28 \$1,030,749,731 \$1,030,749,731 \$	1,700,212,480 \$ \$1,035,20 1,642,400 \$1,700,212,480 29 \$953,114,864 \$53,114,864 \$	1,826,368,919 \$1,084,89 1,883,460 \$1,826,368,919 30 \$1,023,835,967	\$8,573,773,575 TOTAL 5 4,524,426,362
PMPM	Without-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures		PMPM Mem-Mon	\$	1,269,058,737 \$ 8599.37 1,411,053 \$1,269,058,737 26 \$642,883,100 \$42,883,100 \$	1,712,257,751 \$ \$942.54 1,816,642 \$ 11,712,257,751 \$ 27 \$ 873,842,680 \$	2,065,875,689 \$ \$987.78 2,091,433 \$2,065,875,689 28 \$1,030,749,731 \$1,030,749,731 \$	1,700,212,480 \$ \$1,035,20 1,642,400 \$1,700,212,480 29 \$953,114,864 \$53,114,864 \$	1,826,368,919 \$1,084,89 1,883,460 \$1,826,368,919 30 \$1,023,835,967	\$8,573,773,876 TOTAL 5 4,524,426,367 6 4,049,347,214
	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita	1	PMPM Mem-Mon	\$	1.289,058,737 \$ 8599.37 1,411,053 \$ 1,289,058,737 \$ 26 \$ 5642,883,100 \$ 626,176,637 \$ \$ 26 \$	1.712.257.751 \$ \$842.54 1.816.842 \$ 1.712.257.751 \$ \$ \$842.54 1.816.842 \$ 1.712.257.751 \$ 27 \$ \$73.842.680 \$ \$ 638.415.071 \$ 27 \$ 27 \$ 27 \$ 27	2,065,875,689 \$ \$867.76 \$2,001,435 \$2,065,875,689 \$ \$28,065,875,689 \$ \$1,000,749,731 \$ \$1,030,749,731 \$ \$1,030,749,731 \$ \$ \$1,030,749,731 \$ \$ \$ \$1,030,749,731 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1,700,212,480 \$ \$1,035,20 1,642,400 \$ \$1,035,20 1,642,400 \$ \$1,700,212,480 \$ \$1,700,212,480 \$ \$953,114,864 \$ \$ \$747,097,616 \$ \$ \$ \$ \$45,007 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1,826,368,919 \$1,084,89 1,683,490 \$1,826,368,919 30 \$1,023,835,967 1,023,835,967 1,023,835,967 902,532,932	\$8,573,773,876 TOTAL 5 4,524,426,367 6 4,049,347,214
28 27 28 29 30 TOTAL	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita	1	PMPM Mem-Hon Total PMPM	\$	1.289,058,737 \$ 8599.37 1,411,053 \$ 1,289,058,737 \$ 26 \$ 5642,883,100 \$ 626,176,637 \$ \$ 26 \$	1.712.257.751 \$ \$842.54 1.816.842 \$ 1.712.257.751 \$ \$ \$842.54 1.816.842 \$ 1.712.257.751 \$ 27 \$ \$73.842.680 \$ \$ 638.415.071 \$ 27 \$ 27 \$ 27 \$ 27	2,065,875,689 \$ \$867.76 \$2,001,435 \$2,065,875,689 \$ \$28,065,875,689 \$ \$1,000,749,731 \$ \$1,030,749,731 \$ \$1,030,749,731 \$ \$ \$1,030,749,731 \$ \$ \$ \$1,030,749,731 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1,700,212,480 \$ \$1,035,20 1,622,400 \$ \$1,035,20 1,622,400 \$ \$1,700,212,480 \$ \$1,700,212,480 \$ 953,114,864 9 953,114,864 \$ \$ 747,097,616 \$ \$ 29 \$ 4,516,087 \$ \$ \$1,330,50 9	1,826,368,919 \$1,084,89 1,883,489 \$1,826,368,919 30 \$1,023,835,967 1,023,835,967 1,023,835,967 802,532,932	\$8,573,773,876 TOTAL 5 4,524,426,367 6 4,049,347,214
	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita	1	PMPM Mem-Hon Total PMPM	\$	1.269,058,737 \$ 8996.37 \$ 8996.37 \$ 1,411,053 \$1,299,059,737 26 \$042,863,100 \$442,863,100 \$442,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100	17.12.257.751 \$ \$8.42.54 18.16.642 \$1.712.267,751 27 \$873.842.680 \$ 873.842.680 \$ 838.415.071 \$	2.005,875,689 \$ \$897.78 \$2.001,433 \$2.005,875,689 \$ \$ \$2.005,875,689 \$ \$ \$ 1.030,749,731 \$ \$ 1.035,125,988 \$ \$ 1.035,125,988 \$ \$ \$ 51.301,23 \$ \$ \$ \$ 51.301,23 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1,700,212,480 \$ \$1,035,20 \$1,035,20 \$1,035,20 \$1,035,20 \$1,709,212,480 \$1,709,212,480 \$953,114,864 \$953,114,864 \$747,097,616 \$ \$747,097,616 \$ \$1,305,80 \$3,312 \$28 \$1,305,80 \$3,312 \$1,305,80	1,826,388,919 \$1,084.89 1,885,460 \$1,826,368,919 30 \$1,023,835,987 1,023,835,987 1,023,835,987 802,832,932 30 5,820,528 \$1,428,15 4,473	\$8,573,773,575 TOTAL 5 4,524,426,362 3 4,049,347,214 TOTAL
S	Without-Waiver Total Expenditures Hypothetical 1 Fer Capits EC 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capits EC 5 - Group VIII TOTAL HYPOTHETICAL S VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capits EC 6 - CIS	1	PMPM Mem-Hon Total PMPM	\$	1.269,058,737 \$ 8996.37 \$ 8996.37 \$ 1,411,053 \$1,299,059,737 26 \$042,863,100 \$442,863,100 \$442,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100 \$542,863,100	17.12.257.751 \$ \$8.42.54 18.16.642 \$1.712.267,751 27 \$873.842.680 \$ 873.842.680 \$ 838.415.071 \$	2.005,875,689 \$ \$897.78 \$2.001,433 \$2.005,875,689 \$ \$ \$2.005,875,689 \$ \$ \$ 1.030,749,731 \$ \$ 1.035,125,988 \$ \$ 1.035,125,988 \$ \$ \$ 51.301,23 \$ \$ \$ \$ 51.301,23 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1,700,212,480 \$ \$1,035,20 \$1,035,20 \$1,035,20 \$1,035,20 \$1,709,212,480 \$1,709,212,480 \$953,114,864 \$953,114,864 \$747,097,616 \$ \$747,097,616 \$ \$1,305,80 \$3,312 \$28 \$1,305,80 \$3,312 \$1,305,80	1,826,388,919 \$1,084.89 1,885,460 \$1,826,368,919 30 \$1,023,835,987 1,023,835,987 1,023,835,987 802,832,932 30 5,820,528 \$1,428,15 4,473	\$8,573,773,575 TOTAL 5 4,524,426,362 3 4,049,347,214 TOTAL
NYPOTHETICALS VARIANCE 2 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	Without-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL WITH-Waiver Total Expenditures Hypothetical 1 Per Capita EG S - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EG S - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita	1	PMPM Mem-Hon Total PMPM	\$ \$	1.269,058,737 \$ \$999.37 \$ \$999.37 \$ \$1,289,058,737 26 \$642,863,100 \$642,863,100 \$ \$626,176,637 \$ 26 \$1,184,76 \$ \$1,184,76 \$ \$26	1.712.257.751 \$ \$5842.54 1.816.642 \$1.712.257.751 27 \$873.842.680 \$73.842.680 \$73.842.680 \$73.842.680 \$73.842.680 \$73.842.680 \$73.842.680 \$73.842.680 \$73.842.680 \$73.842.680 \$73.842.680	2.065,875,689 \$ \$897,78 \$ \$ \$2.01,433 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1.700.212.480 \$ \$1.035.20 \$1.035.20 \$1.035.20 \$1.035.20 \$1.035.20 \$1.035.20 \$1.700.212.480 \$1.700.212.480 \$953.114.864 \$953.114.864 \$747.097.616 \$1.035.20 \$	1,000,500,510 \$1,004,60 \$1,004,	\$8,673,773,675 TOTAL 5 4,524,426,367 4,049,347,214 TOTAL 10,337,015
##POTHETICALS TEST 3 Without-Maiver Total Expenditures ##pothetical 3 Per Cepta	With-Waiver Total Expenditures Hypothetical 1 Per Capita EGS - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EGS - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without Waiver Total Expenditures Hypothetical 2 Per Capita EGG - COIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EGG - COIS TOTAL With-Waiver Total Expenditures	1	PMPM Mem-Hon Total PMPM	\$ \$	1.269,058,737 \$ \$999.37 \$ \$999.37 \$ \$1,289,058,737 26 \$642,863,100 \$642,863,100 \$ \$626,176,637 \$ 26 \$1,184,76 \$ \$1,184,76 \$ \$26	1.712.257.751 \$ \$5842.54 1.816.642 \$1.712.257.751 27 \$873.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640 \$73.842.640	2.065,875,689 \$ \$897,78 \$ \$ \$2.01,433 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1,700,212,480 \$ \$1,005,20 \$1,005,20 \$1,005,20 \$1,005,20 \$1,709,212,480 \$28,5114,664 \$933,114,664 \$747,097,616 \$ \$1,000,00 \$1,0	1.020, 300, 519 1.020, 800, 519 1.020, 800 1	\$8,573,773,575 TOTAL 5 4,524,426,362 8 4,049,347,214 TOTAL 10,337,015 TOTAL
28 27 28 29 30 TOTAL	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita EGS - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EGS - Group VIII TOTAL WYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EGS - CIS TOTAL WITH-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL Without-Waiver Total Expenditures	1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$ \$	1.269,058,737 \$ \$899.37 \$ \$899.37 \$ 1,411,003 \$11,289,098,737 26 \$642,883,100 \$442,883,100 \$442,883,100 \$542	1.712.257.751 \$ \$842.54 1.816.642 \$1.712.267,751 27 \$573.842.680 \$ 838.415.071 \$ 27 27 27 27 27 27 27 28 28 28 28 28 28 28 28 28 28 28 28 28	2.005,875,689 \$ \$587.75 2.001,433 \$2,065,875,689 28 \$1,030,749,731 \$1,030,749,731 \$1,035,125,686 \$ 28 \$1,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23	1,700,212,480 \$ \$1,055,20 \$1,055,20 \$1,055,20 \$1,055,20 \$1,709,212,480 \$1,709,212,480 \$953,114,864 \$953,114,864 \$747,097,616 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$4,305,804 \$1,305,80	1,220,368,519 51,064,69 51,064,69 51,064,69 51,220,369,519 30 51,022,655,567 1,022,655,567 1,022,655,567 5,220,523 51,420,15 5,620,528 51,420,15 5,620,528	\$8,573,773,575 TOTAL \$ 4,524,426,362 \$ 4,049,347,214 TOTAL TOTAL TOTAL 10,337,015
28 27 28 29 30 TOTAL	Without-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - GS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - GS TOTAL HYPOTHETICALS VARIANCE 2 HYPOTHETICALS TEST 2 Without Waiver Total Expenditures	1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$ \$	1.269,058,737 \$ \$899.37 \$ \$899.37 \$ 1,411,003 \$11,289,098,737 26 \$642,883,100 \$442,883,100 \$442,883,100 \$542	1.712.257.751 \$ \$842.54 1.816.642 \$1.712.267,751 27 \$573.842.680 \$ 838.415.071 \$ 27 27 27 27 27 27 27 28 28 28 28 28 28 28 28 28 28 28 28 28	2.005,875,689 \$ \$587.75 2.001,433 \$2,065,875,689 28 \$1,030,749,731 \$1,030,749,731 \$1,035,125,686 \$ 28 \$1,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23	1,700,212,480 \$ \$1,055,20 \$1,055,20 \$1,055,20 \$1,055,20 \$1,709,212,480 \$1,709,212,480 \$953,114,864 \$953,114,864 \$747,097,616 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$4,305,804 \$1,305,80	1,220,368,519 51,064,69 51,064,69 51,064,69 51,220,369,519 30 51,022,655,567 1,022,655,567 1,022,655,567 5,220,523 51,420,15 5,620,528 51,420,15 5,620,528	\$8,573,773,575 TOTAL \$ 4,524,426,362 \$ 4,049,347,214 TOTAL TOTAL TOTAL 10,337,015
Total Parallel Par	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita ECS - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita ECS - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita ECS - CIS TOTAL WIth-Waiver Total Expenditures Hypothetical 2 Per Capita ECS - CIS TOTAL HYPOTHETICALS VARIANCE 2 HYPOTHETICALS VARIANCE 2 HYPOTHETICALS VARIANCE 2 HYPOTHETICALS VARIANCE 2	1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$ \$	1.269,058,737 \$ \$899.37 \$ \$899.37 \$ 1,411,003 \$11,289,098,737 26 \$642,883,100 \$442,883,100 \$442,883,100 \$542	1.712.257.751 \$ \$842.54 1.816.642 \$1.712.267,751 27 \$573.842.680 \$ 838.415.071 \$ 27 27 27 27 27 27 27 28 28 28 28 28 28 28 28 28 28 28 28 28	2.005,875,689 \$ \$587.75 2.001,433 \$2,065,875,689 28 \$1,030,749,731 \$1,030,749,731 \$1,035,125,686 \$ 28 \$1,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23 \$51,031,23	1,700,212,480 \$ \$1,055,20 \$1,055,20 \$1,055,20 \$1,055,20 \$1,709,212,480 \$1,709,212,480 \$953,114,864 \$953,114,864 \$747,097,616 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$3,312 \$4,516,087 \$1,305,80 \$4,305,804 \$1,305,80	1,220,368,519 51,064,69 51,064,69 51,064,69 51,220,369,519 30 51,022,655,567 1,022,655,567 1,022,655,567 5,220,523 51,420,15 5,620,528 51,420,15 5,620,528	\$8,573,773,575 TOTAL \$ 4,524,426,362 \$ 4,049,347,214 TOTAL TOTAL TOTAL 10,337,015
PMPM \$3.231.17 \$3.386.27 \$3.548.81 \$3.719.15 \$3.389.67 \$3.397.67	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita ECS - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita ECS - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita ECS - CIS TOTAL WIth-Waiver Total Expenditures Hypothetical 2 Per Capita ECS - CIS TOTAL HYPOTHETICALS VARIANCE 2 HYPOTHETICALS VARIANCE 2 HYPOTHETICALS VARIANCE 2 HYPOTHETICALS VARIANCE 2	1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$ \$	1269,058,737 \$ \$999,37 \$ \$999,37 \$ \$1,289,058,737 26 \$642,853,100 \$442,853,100 \$ \$628,176,637 \$ 26 \$1,184,76 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1.712.257.751 \$ \$842.25 \$842.25 \$1.712.257.751 27 \$873.842.580 \$73.842.580 \$73.842.580 \$73.842.580 \$73.842.580 \$74.241.681 \$75.842.880 \$7	2,065,875,688 \$	1.700.212.480 \$ 8.00.212.480 \$ 8.00.212.480 \$ 1.642.40	1.004.006.5110 \$1,004.00 \$1,004.00 \$1,004.00 \$1,004.00 \$1,004.00 \$1,004.00 \$1,004.00 \$1,003.055.987 \$1,003.055.987 \$1,003.055.987 \$1,003.055.987 \$1,003.055.987 \$1,003.055.987 \$1,005.050 \$1,005.05	\$8,673,773,676 TOTAL \$ 4,624,426,367_ \$ 4,624,426,367_ \$ 10,337,018 TOTAL TOTAL TOTAL \$ 10,337,018 TOTAL \$ 279,101
TOTAL \$. \$. \$. \$. \$. \$. \$. \$. \$. \$	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL WITH-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Fer Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 8 - CIS TOTAL Hypothetical 2 Per Capita EG 9 - CIS TOTAL Hypothetical 2 Per Capita EG 9 - CIS	1 1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$ \$	1269,058,737 \$ \$999.37 \$ \$999.37 \$ \$1,298,058,737 26 \$642,863,100 \$42,863,100 \$542,863,100 \$51,184,76 \$51,184	17.12.257.751 \$ \$5842.54 1,816.642 \$1,712.257.751 27 \$873,842.680 \$73,842.680 \$73,842.680 \$73,842.680 \$74,842.680 \$74,842.680 \$75,842.680 \$76,841.637 \$7 \$7 \$81.241.63 \$7 \$81.241.63 \$7 \$81.241.63	2.065,875,689 \$ \$897,78 \$ \$ \$2.001,433 \$ \$ \$2.065,875,689 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1,700,212,480 \$ \$1,005,20 \$1,005,20 \$1,005,20 \$1,700,212,480 \$1,700,212,480 \$95,114,864 \$95,114,864 \$747,007,616 \$1,007,6	1.004.090.5110.450.510.510.450.510.450.5110.450.5110.450.5110.450.5110.450.5110.450.5110.450.510.450.5110.450.5110.450.5110.450.510.450.510.450.510.450.510.450.510.450.510.450.510.450.510.450.510.450.510.450.510.450.510.450.500.510.450.510.450.500.500.500.500.500.500.500.500.50	\$8,673,773,676 TOTAL \$ 4,624,426,367_ \$ 4,624,426,367_ \$ 10,337,018 TOTAL TOTAL TOTAL \$ 10,337,018 TOTAL \$ 279,101
With-Waiver Total Expenditures 28 27 28 29 30 TOTAL	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL WITH-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Fer Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 8 - CIS TOTAL Hypothetical 2 Per Capita EG 9 - CIS TOTAL Hypothetical 2 Per Capita EG 9 - CIS	1 1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$ \$	1.269,058,737 \$ \$999.37 \$ \$999.37 \$ 1.411,053 \$11,289,098,737 26 \$542,893,100 \$442,893,100 \$42,893,100 \$542,	1.712.257.751 \$ \$042.54 1.816.642 \$1.712.287.751 27 \$873.842.680 \$ 873.842.680 \$ 838.415.071 \$ 27 27 27 - \$ - \$ - \$ - \$ 27 - \$	2.065,875,689 \$ \$897.76 \$ \$897.75 \$ \$ \$2.061,455 \$ \$ \$2.065,875,689 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1,700,212,480 \$ \$1,052,50 \$1,052,50 \$1,052,50 \$1,052,50 \$1,709,212,480 \$95,114,664 \$95,114,664 \$95,114,664 \$747,097,616 \$ \$1,050,50 \$1,0	1,220,366,519 51,054,69 11,052,605 11,226,369,519 30 51,022,605,567 1,022,605,567 1,022,605,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607 1,022,607	\$8,673,773,676 TOTAL \$ 4,624,426,367_ \$ 4,624,426,367_ \$ 10,337,018 TOTAL TOTAL TOTAL \$ 10,337,018 TOTAL \$ 279,101
28 27 28 29 30 TOTAL	Without-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Fer Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Fer Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Fer Capita EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capita EG 8 - CIS TOTAL Hypothetical 2 Per Capita EG 9 - CIS TOTAL Hypothetical 2 Per Capita EG 9 - CIS Hypothetical 2 Per	1 1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$	1.269,058,737 \$ 8399.37 \$ 8399.37 \$ 1,411,003 \$11,289,058,737 26 \$642,863,100 \$ 642,863,100 \$ 642,863,100 \$ 626,175,637 \$ 26 \$51,184,76 \$ \$ \$51,184,76 \$ \$51,18	1.712.257.751 \$ \$842.54 1.816.642 \$1.712.257.751 27 \$873.842.680 \$ 873.842.680 \$ 873.842.680 \$ 27 27 27 27 28 27 28 27 27 27 28 38.415.071 \$ 38.415.071 \$	2.005,875,689 \$ \$897.78 \$2.001,433 \$2.005,875,689 28 \$1,030,749,731 1,030,749,731 28 \$1,030,749,731 28 \$51,301,23 \$51	1,700,212,480 \$ \$1,055,20 \$1,055,20 \$1,055,20 \$1,055,20 \$1,709,212,480 \$1,709,212,480 \$953,114,864 \$ 953,114,864 \$ 747,097,616 \$ \$ 4,516,087 \$ \$1,305,69 \$3,312 \$4,516,087 \$ \$ 1,22,143 \$ \$ 122,143 \$ \$ 122,143 \$ \$ 122,143 \$ \$ 122,145 \$ \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,718,15 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,718,15 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,718,15 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ 1,316,585 \$ \$ 3,312 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1	1,220,368,519 51,064,69 51,064,69 51,064,69 51,264,69 51,264,69 51,264,69 51,262,365,59 51,262,362,59 51,262,37 51,262	\$8,573,773,575 TOTAL 10,327,015 TOTAL
TOTAL \$ - \$ - \$ 11,983,484 \$ 15,447,190 \$ 27,430,674	Without-Waiver Total Expenditures Hypothetical 1 Per Capits EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capits ES 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capits ES 5 - Group VIII HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capits EG 6 - CIS TOTAL With-Waiver Total Expenditures Hypothetical 2 Per Capits EG 6 - CIS TOTAL HYPOTHETICALS VARIANCE 2 Hypothetical 2 Per Capits EG 6 - CIS Without-Waiver Total Expenditures Hypothetical 2 Per Capits EG 7 - CIS Community Transition Pilot TOTAL HYPOTHETICALS TEST 3 Without-Waiver Total Expenditures Hypothetical 3 Per Capits EG 7 - CIS Community Transition Pilot	1 1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$	1.269,058,737 \$ 8399.37 \$ 8399.37 \$ 1,411,003 \$11,289,058,737 26 \$642,863,100 \$ 642,863,100 \$ 642,863,100 \$ 626,175,637 \$ 26 \$51,184,76 \$ \$ \$51,184,76 \$ \$51,18	1.712.257.751 \$ \$842.54 1.816.642 \$1.712.257.751 27 \$873.842.680 \$ 873.842.680 \$ 873.842.680 \$ 27 27 27 27 28 27 28 27 27 27 28 38.415.071 \$ 38.415.071 \$	2.005,875,689 \$ \$897.78 \$2.001,433 \$2.005,875,689 28 \$1,030,749,731 1,030,749,731 28 \$1,030,749,731 28 \$51,301,23 \$51	1,700,212,480 \$ \$1,055,20 \$1,055,20 \$1,055,20 \$1,055,20 \$1,709,212,480 \$1,709,212,480 \$953,114,864 \$ 953,114,864 \$ 747,097,616 \$ \$ 4,516,087 \$ \$1,305,69 \$3,312 \$4,516,087 \$ \$ 1,22,143 \$ \$ 122,143 \$ \$ 122,143 \$ \$ 122,143 \$ \$ 122,145 \$ \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,718,15 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,718,15 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,718,15 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ 1,316,585 \$ \$ 3,312 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1,316,585 \$ \$ 3,312 \$ \$ 1	1,220,368,519 51,064,69 51,064,69 51,064,69 51,264,69 51,264,69 51,264,69 51,262,365,59 51,262,362,59 51,262,37 51,262	\$8,573,773,575 TOTAL 3 4,524,426,362 4,049,347,214 TOTAL TOTAL TOTAL 3 10,337,015 TOTAL 3 279,101 TOTAL
	Without-Waiver Total Expenditures Hypothetical 1 Fer Capits EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capits EG 5 - Group VIII TOTAL WITH-Waiver Total Expenditures Hypothetical 1 Per Capits EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capits EG 6 - CIS TOTAL HYPOTHETICALS VARIANCE 2 HYPOTHETICALS TEST 3 Without-Waiver Total Expenditures Hypothetical 2 Per Capits EG 6 - CIS TOTAL HYPOTHETICALS TEST 3 Without-Waiver Total Expenditures Hypothetical 2 Per Capits EG 7 - CIS Community Transition Pilot TOTAL With-Waiver Total Expenditures	1 1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$	1.269,058,737 \$ 8399.37 \$ 8399.37 \$ 1,411,003 \$11,289,058,737 26 \$642,863,100 \$ 642,863,100 \$ 642,863,100 \$ 626,175,637 \$ 26 \$51,184,76 \$ \$ \$51,184,76 \$ \$51,18	1.712.257.751 \$ \$8.842.54 1.816.642 \$1.712.257.751 27 \$873.842.680 \$73.842.680 \$73.842.680 \$73.842.680 \$74.680 \$75.842.680 \$7	2.065,875,689 \$ \$ \$87,76 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1.700.212.480 \$ \$1.035.20 \$1.035.20 \$1.035.20 \$1.035.20 \$1.035.20 \$1.035.20 \$1.700.212.480 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.864 \$2.035.114.865 \$2.03	1.004.006.5110 \$1.004.00 \$1.004	\$8,673,773,675 TOTAL 4,624,426,362 4,049,347,214 TOTAL 10,337,016 TOTAL 10,057,914 10,057,914 10,057,914 10,057,914
NYPOTHETICALS VARIANCE 3 \$ - \$ - \$ - \$ 333,101 \$ 428,020 \$ 761,121	Without-Waiver Total Expenditures Hypothetical 1 Fer Capits EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capits EG 5 - Group VIII TOTAL WITH-Waiver Total Expenditures Hypothetical 1 Per Capits EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capits EG 6 - CIS TOTAL HYPOTHETICALS VARIANCE 2 HYPOTHETICALS TEST 3 Without-Waiver Total Expenditures Hypothetical 2 Per Capits EG 6 - CIS TOTAL HYPOTHETICALS TEST 3 Without-Waiver Total Expenditures Hypothetical 2 Per Capits EG 7 - CIS Community Transition Pilot TOTAL With-Waiver Total Expenditures	1 1	PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$ \$	1.269,058,737 \$ 8996.27 \$ 8996.27 \$ 1.461,050 \$11,289,058,737 26 \$042,803,100 \$442,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$542,803,100 \$543,100	17.12.257.751 \$ \$042.54 18.16.642 \$1.712.257.751 27 \$073.842.680 \$73.842.680 \$873.842.680 \$ \$27 \$1.241.63 \$ \$27 \$ \$53.386.27 \$ \$53.386.27 \$ \$27	2.065,875,689 \$ \$897.78 \$2.051,433 \$2.065,875,689 28 \$1,000,749,731 1,033,749,731 1,033,749,731 28 \$1,035,125,989 \$ 28 \$1,301,23 \$ \$1,035,125,989 \$ 28 \$ \$28 \$ \$51,301,23 \$ \$ \$28 \$ \$51,301,23 \$ \$ \$28 \$ \$3,548,81 \$ \$ 28 \$ \$3,548,81	1,700,212,480 \$ \$1,005,20 \$1,005,20 \$1,005,20 \$1,005,20 \$1,709,212,480 \$1,709,212,480 \$953,114,864 \$953,114,864 \$747,007,616 \$1,005,619 \$1,005,	1.020, 308, 519 1.020, 508, 519 1.020, 609 1	\$8,673,773,675 TOTAL 4,624,426,362 4,049,347,214 TOTAL 10,337,016 TOTAL 10,057,914 10,057,914 10,057,914 10,057,914
	Without-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL With-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL WITH-Waiver Total Expenditures Hypothetical 1 Per Capita EG 5 - Group VIII TOTAL HYPOTHETICALS VARIANCE 1 HYPOTHETICALS TEST 2 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL HYPOTHETICALS TEST 3 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EG 6 - CIS TOTAL HYPOTHETICALS TEST 3 Without-Waiver Total Expenditures Hypothetical 2 Per Capita EG 7 - CIS Community Transition Pilot TOTAL With Waiver Total Expenditures Hypothetical 3 Per Capita EG 7 - CIS Community Transition Pilot TOTAL With Waiver Total Expenditures Hypothetical 3 Per Capita EG 7 - CIS Community Transition Pilot TOTAL	1 1	PAPM Mem-Mon Total PAPM Mem-Mon Total PAPM Mem-Mon	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1.269,058,737 \$ 8399.37 \$ 8399.37 \$ 1.411,053 \$11,289,058,737 26 \$642,863,100 \$442,863,100 \$51,184.76 \$ \$1,184.76 \$ \$ 26 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1.712.257.751 \$ \$842.54 \$1.816.642 \$1.712.257.751 27 \$873.842.680 \$73.842.680 \$873.842.680 \$ \$27 \$1.241.63 \$ \$ \$27 \$ \$5.3.86.27 \$ \$5.3.86.27 \$ \$5.3.86.27 \$ \$5.3.86.27 \$ \$5.3.86.27 \$ \$5.3.86.27 \$ \$5.3.86.27	2.065,875,689 \$ \$897.78 \$2.061,433 \$2.065,875,689 28 \$1,030,749,731 1,030,749,731 1,030,749,731 28 \$1,030,749,731 28 \$51,301,23 \$51,	1,700,212,480 \$ \$1,055,20 \$ \$1,055,20 \$ \$1,055,20 \$ \$1,055,20 \$ \$1,055,20 \$ \$1,709,212,480 \$ \$1,709,212,480 \$ \$1,055,20 \$ \$1,0	1,220,366,519 \$1,024,69 \$1,024,69 \$1,024,69 \$1,024,69 \$1,024,69 \$1,024,69 \$1,022,695,567 \$1,022,695,567 \$0,023,695,697 \$0,023,695,697 \$0,023,695,697 \$0,023,695,697 \$0,023,695,697 \$0,023,695,697 \$0,023,695,697 \$0,023,695,697 \$0,023,695,697 \$0,023,695,695 \$1,023,695,695 \$1,023,695,695 \$1,023,695,695 \$1,023,695,695 \$1,023,695 \$1,02	\$8,573,773,575 TOTAL 3 4,524,426,362 3 4,049,347,214 TOTAL TOTAL TOTAL 10,337,015 TOTAL 3 10,057,914 5 279,101 TOTAL

 Yes_No
 Waiver List
 Demonstration Reporting Start DY
 26

 Yes
 MAP WAIVERS
 Demonstration Reporting End DY
 30

 No
 Not Applicable

 Per Capita or Aggregate
 1902 R 2

 Per Capita
 1902 R 2X

 Aggregate
 1902R2

 AFDC
 Aged w/Mcare

No Phase-Down
Savings Phase-Down
Aged w/o Mcare
Aged with Medicare - MFP
Aged without Medicare - MFP

Actuals and Projected
Actuals Only
B/D w/Mcare
B/D w/o Mcare

Actuals + Projected

Blind/Disable without Medicare - MFP

Blind/Disabled with Medicare - MFP

MAP_ADM

Breast Cervical Cancer Treatment (BCCT)

1,115

MAP+ADM Waivers

MAP Waivers Only

CURRENT POP

Current-Hawaii Quest

Demo Elig Adults

EG 7 – CIS Community Transition Pilot

Expansion State Adults FosterCare(19-20) HawaiiQuest-1902(R)(2)

HCCP

EG 6 - CIS

HealthQuest-Current HealthQuest-Others Med Needy Adults Med Needy Children MFCP

Newly Eligible Adults NH w/o W Opt St Pl Children

Others

Others-Hawaii Quest

OthersX QUEST ACE RAACP

St PI Adults-Preg Immig/COFAs

State Plan Adults
State Plan Children
Supp. - Private
Supp. - State Gov.
UCC-Governmental
UCC-GOVT LTC
UCC-Private
VIII-Like Group
ADM WAIVERS

Reporting Net Variance

\$ 1,517,469,929

Schedule C CMS 64 Waiver Expenditure Report Cumulative Data Ending Quarter/Year : 1/2023

State: Hawaii

	_																		Summary	of Expenditur Waiver: 11W	res by Waive V00000	er Year																		
P Waivers																				Total Comp	utable																			
me	A 01	1 02	. 03	04	05	06	07	. 0:	8 09	9 1	0 1:	1 1	2 13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	5 36	37	38	39	40 Total
Total	•							0	•	4	•											•	•	•	•						•	•		•		• •			•	
																				Federal Si	hare																			
e os	A 01	1 02	. 03	04	05	i 06	07	. 0:	8 09	9 1	0 1	1	2 13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	5 36	37	38	39	40 Total
•								0			•									۰	٠	٠	۰	۰	۰	٠	٠		٠	٠	۰	۰	۰	•					•	
Vaivers																																								
	Δ 01	1 02	. 03	04	. 05	. 06	07	, 0:	8 09	9 1	0 1:	1 13	2 13	14	15	16	. 17	, 18	19	Total Comp	utable 21	22	23	24	25	26	27	28	29	30	31	32	33	34	1 39	5 36	37	38	39	40 Total
				-				•							-	-				-	-			-		E, 600, 500	(4,811,100)	-		-										40 Total
																				Federal Si	hare																			
	A 01	1 02	. 03	04	05	06	07	. 0	8 09	9 1	0 1:	1 1	2 13	14	15	16	17	18	19	20	21	22	23	24	25	26 3,567,666	27	28	29	30	31	32	33	34	35	5 36	37	38	39	40 Total
	• •	• •				•			•	•	•	•								٠	٠	۰	۰		٠	1,947,664	(2,990,180)		٠	۰	۰	۰	٠			•				0 2,812,126
																			Summary	of Expenditur Waiver: 11W	res by Waive V00001	er Year																		
'aivers																																								
																				Total Comp	utable																			
y M M M	A 01 0 30,81,91 0 171,204,809 0 (4,241,309) 0 131,802 0 166,009,864	1 02	. 03	04	. 05	(28,280)		0	8 09	9 1	0 1	1	2 13	14	15	16	. 17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	5 36	37	38	39	0 N(ME, NE 0 171, 176, 601
	0 321,862 0 368,009,664 0 0			8	8	0	0		0 0	0 0 0				(280)	0 0 121,279,664 2,624,989	0 0 834,992,648 37,590,167	0 0 890,734,637 34,834,002	0 836,518,117 18,718,987	0 0 309,336,648 20,488,389	0 0 284,750,729 34,825,806	0 0 304,909,460 37,994,603	0 0 827,884,987 68,712,106	0 0 120,894,125 04,331,285	0 0 10,130,146 10,094,164	0 0 561,530,609 81,120,800	0 0 NF,404,961 64,283,906	0 0 395,179,660 200,779,680	0 0 000,516,129 120,012,500	0 0 160,185,061 16,801,365		0	0		0	0				0 0	40 Total - All San
	0 0	0 0	9	9	9	0 0 0	0 0		_ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 0 0	- 6 0 0 0			0 (200) 0 0 (17,000) (20,001)	0 121,279,864 2,624,889 0 0 11,794,862 81,504,862	0 834,952,648 27,550,357 0 0 74,760,539 231,664,665 0	100,734,437 34,810,000 0 11,000,000 204,400,132 0 0 101,182 0 0 218,841,735 0 0 218,841,735 0 0 218,841,735 0 0 218,841,735 0 0 218,841,735	20,728,027 20,728,027 0 0 77,601,006 207,012,302 0 0 0 000,028	0 589, 134, 565 24, 646, 148 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	284,730,729 14,823,306 0 043,203,586 168,440,600 0 369,200 0 0 40,803,000 0 0 2 2 40,803,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	364, 103, 462 37,984, 862 0 98, 807, 288 290, 200, (80 0 100, 108 0 0 100, 108 100, 108 100, 108 100, 108 100, 108	307,860,987 68,772,100 (672,100) (124,660) 184,862,887 200,100,988 (104,700) (81,120) 0 0 0 (8,720) 864,652,887 864,652,887	0 120(804,120 04,335,20 (507,140) (64,522) 135,364,686 110,389,367 (181,640) (74,23) 222,889 0	0 (10) 320 100 100, 000, 100 100, 100 100 100 100	0 541,335,609 81,325,000 (545,336, (645,336, 264,325,609 (897,922) (280,331, 207,922 0	0 NET, MAR, MEI 64, 2373, MEE 64, 2373, MEE 6400, 2384] (217, 2384) 239, GEA, MEE (2364, MEE) (2364, MEE) (237, 2382) 6, 2322 0	0 810,339,566 200,739,680 (12,936) 0 366,682,380 364,023,027 (27,985) (2,236) 39,663	0 409,314,129 119,012,000 0 204,274,100 209,274,100 0 0 12,762	0 71, 316, 363 212,676,966		0 0	0 0	0	0	. 0	- 0 0 0 0 0 0 0	0 0 0	a a a	0 0 0	0 (3,007,500) 0 (383,736) 0 1,779,843,843 0 4,367,748,843 0 (1,748,507)
	0 0 0 0 0 001,000,000 0 272,778,688	0 0	8			0 0 1,661,526 0	0 0 200,404,90.7 0	75,321,10	0 0 0 0 8 0	0 0	0 0			0 0	(2)	4,018	565,812 0 0	0 804,038 0	710,145 0	865,200 G G	363,366 0	277,606 0 0	(74,228) 223,869 0 0	(200, K20) 100, 867 0 0	(28Q311) 107,700 0	6,322 0 0	(2,296) 30,668 0 0	10,762 0 0	0 0 0		0	0 0		0	0 0	0 0 0 0 0 0		0 0 0	0 0	0 (600,820) 0 3,830,789 0 780,784,683 0 273,776,688
	0 0 001,514,050 0 272,775,688 0 0 0 0 0 0 0 0 0 0 200,125 0 1,984,346 0 1,781,348	0 0	1	1		0 0	0	75,521,15 40,014,79 136,63	15 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0 11,70 0 0 0 0 0 MA,81 0 3M,810,21 10 99,234,00	0 118,560 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	127,882,800	129,416,848	154,209,257 0 91,499	0 277,802,609 81,866 91,812 681,209 0 15,875 7,755 981,510 0 14,209,737 207,566	201,638,981 0 94,198	288,940,778 0 187,408	364,752,685 0 71,622	227,396,498 0 176,836	61,812,803 0 171,682	12,668 291,868,127 703,624	(0,774) SER, SET, SET SER, 274	0 795 677,326,996 887,664	0 587,028,595 1,838,600	790,507,966 2,806,888	0 138,81,81 1,789,162	70,822,960 2,030,918	0 854,883,590 1,786,699	0 896,875,000 724,796		0		0	0	0	0 0			0	0 40,042,785 0 1,542,795,286 0 4,834,995,934 0 13,983,295
	0 0,884,768 0 1,783,868 0 0	207,270 0 1 190,490 1 223,485	2,684,176 0 12,110,775 1,122,818	1,486,864 0 10,000,008 8,486,465	7,87,60 2,676,60 0 2,676,60 0	1,394,666 0 10,651,180 1,903,013	0 8,874,702 3,806,673 0	64,638,70 21,030,39	0 0 0 280,388,670 10 68,641,999 0 0	0 364,916,31 10 364,916,31 10 99,316,00	0 0 H 390,471,380 M 98,728,111	(2,825,150 (625,66) 56,500	0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1	181,120 0 0 113,481	601,209 0 0 0,305	0 0 0 117,005	0 0 100,887	0 0	0		9	0 0	0 0	0 0	0	0	0		8		0	0 0	0 0	0	0	0 0			0 0	0 E36,470 0 1,007,884,866 0 287,824,760 0 586,656
	0 0	0 0		9		0	0		0 0	0	0 0	(2,325, 25) (427, 66 34, 30) 75, 427		0 123,819 0 1,100,418	7,705 903,503 0 16,399,797	201, A28, R81 94, 138 9, 201 0 0 117, 03 1, 780 0 0 0 0 218, 182 0 0	0	0	0	1,885	234,960,875	0 0 165,225,906 0	0 0 110,173,766 0	136,900,475	190,891,331	114,607,706 0	298,798,962 0	280,272,365	80,126,002 0		0	0	0	0	0	0 0			0	0 31,876 0 706,852 0 1,860,869,811 0 21,880,156
	0 288,112,808 0 0 0 (21,809,127)	0		9	9	784,812 0 0	M,680,733	80,507,68 38,542,10	0 0 10 0 18 0	0	0 0	76,617	121,082	#00% 0 0	207,586 0 0	210,100 0 0	0 0	0				0	0	0	0	0	0				0	0	0	0	0	0 0				0 75,236 0 85,287,000 0 31,142,108 0 (21,887,727)
	0 0	0 0	0 0 0	0 0 0	0 0 0	0 0	0 0 0	(3	0 0 0 0 10 218 16 2,008 0 0	0 0 8 1	0 0 0 0 8 35,34	111,962,790 361,801,001	1 0 1 138,021,622 1 176,673,728	7,862,679 0 101,050,681 150,882,585	17,613,929 0 129,229,128 168,813,229	0 30,990 111,860,148 202,898,810	2,635,860 121,596,289 211,965,838	2,628,627 312,927,966 387,768,000	2,879,646 180,118,272 219,842,600	0 987,021 80,894,875 206,195,460	0 1,562,365 202,615,960 268,660,968	0 1,600,766 172,952,208 806,184,183	2,000,606 160,002,308 316,389,868	2,820,028 180,720,836 870,170,666	4,045,098 295,652,778 595,785,762	0 8,327,086 361,876,005 362,806,760	2,396,507 200,602,618 630,517,967	1,646,060 227,220,660 458,348,500	0 0 300,960,128 387,760,230		0 0	0 0	0 0	0	0	0 0 0 0 0 0	0	0		0 21,295,635 0 27,632,336 0 3,735,675,605 0 4,875,135,500
	0 0	0 0				0	0		0 0 0 0 0 0	0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	111,000,700 201,001,001 15,000,121 22,000,100	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	154,209,337 14,609 15,001 110,100 0,001 120,002 120,003 120,003 120,003 0,100,003 0,100,003 100,003	0 14,887,817 17,602,809 00 109,275,108 00 0,00 14,814,580 0 7,300,000	22,867,630 24,867,630 34,860,141 312,860,140 312,870,150 0 0 24,107,600 7,100,000	20,000,000 2,020,000 220,500,200 220,500,200 220,600,000 20,000,000 7,000,000	27,982,005 2,622,027 112,917,986 267,710,000 0 04,909,822 609,961	0 76,412,848 0 2,871,648 180,118,777 218,842,840 0 0 12,346,879 0 88,824,828	26,173,607 0 907,922 80,816,871 200,109,401 0 3,956,911 0 20,400,412 71,406,422	20, 200, 200, 200, 200, 200, 200, 200,	174,005,786 174,005,188 806,184,185 0 0 4,184,188 0 0 1,484,188	2,000,606 181,012,339 134,389,868 0 0 981,179 0 64,030,000	0	0	0	0						0	0	0	0 0			0	0 7,500,002 0 17,833,230 0 238,230,036 0 600,041
	0 1,492,419,190	10 675,00	9,99,10	10,007,000	10,004,000	e 26/200/221	228,727,968	8 266,800,2	11 29(J4(48	0 100 300,276,7	D 104,860,0		m 44/2/30	04,24,30	781,030,000	UNUMUM	LIES MORE	0 1,007,017,08	1,465,175,000	75,000,225 774,824,287	1,700,700,725	1,886,636,189	Taudandana D	2,522,696,698	1,307,120,139	2,090,810,197	2,494,500,885	2,762,554,567	LINCHAR		•					•				0 77,000,002 0 30,000,004,603
																				Federal Si	hare																			
	A 01	1 02	03	04	05	06	07	0:	8 09	9 1	0 1	1 1	2 13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	5 36	37	38	39	40 Total 0 8,00,00 0 8,70,70
	0 23,490,823 0 86,769,823 0 (4,204,386 0 34,284,827 0 0	0 0	0	9	0	0 0	0		0 0 0	0	0 0			(199)	0 0 81,104,508 1,622,868	211,862,765 11,832,762	228,328,339 228,328,339	0 0 36,68,86	0 0 179,767,156	90,875,346	0 0 0 289,104,079	0 0 0 163,183,080	0 0 0 174,947,428	0 0 180,187,275	0 0 0 804,987,760	0 0 230,882,875	210,136,610	0 0 0 200,689,116	0 0 111,699,386 33,622,668	9	0 0	0 0	0 0	0	0	0 0		9	0 0	0 (4,200,186) 0 60,696 0 74,014,827 0 2,777,914,217
	0 0	0 0	9	9	9	0 0	0		0 0	0 0 0	0 0			0 (21,480) (21,480)	0 0 21,277,00 54,513,211	0 0 00,007,636 161,799,152		201,611,811 9,984,628 0 29,111,127 180,299,88	0 179,767,136 12,421,760 0 0,400,375 10,422,789	95,873,268 7,728,680 0 0 25,890,237 76,872,888 0 0 201,800	283, 104, 079 283, 754, 668 0 0 0 51, 663, 250 250, 766, 276 0 279, 276	183,181,080 27,680,796 (200,676 (2.730) 86,030,126 100,630,630 (27,680) (23,280) 0 0	0 178,857,638 20,354,793 (273,628) (24,377) 88,961,330 187,660,679 (180,328) (60,338) 133,669	0 161, 167, 275 80, 621, 086 (226, 616) (M, 525) 84, 816, 816 216, 542, 276 (200, 647) (M, 506) 27, 773	0 804,887,700 04,882,803 (334,744) (28,817) 184,742,800 (294,572,800 (234,174) 62,338 0	0 203,882,095 86,827,085 (277,025) 10,985 830,187,067 (206,189) (43,986) 1,667	212,130,600 62,000,800 (20,000) 96,800,760 221,000,600 (23,700) (1,307) 20,320	204,689,116 79,810,790 0 99,810,870 210,810,417 0 4,800	0 0 04,898,111 98,992,668		0	0	0	0	0	0 0			0 0	0 (1,881,09) 0 (98,13) 0 1,000,693,633 0 2,883,707,630
	0 0 0 0 0 267,680,665	0 0				904,176	0 0 81,534,564	40,666,14	0 0	0	0 0			0	(1)	2,794 0	0 361,286	0 0 M2,327		201,005	276,276	(171,000) (131,200) 201,077	(00,358) 152,685 0	(30,607) (84,500) 27,773 0	(234,092) (325,376) 62,336 0	(20,00) (21,00) 1,607	(1,507) (1,507) 20,129 0	1,808			0	0	0	0	0	0 0			0	0 (101,110) 0 (171,400) 0 2,590,006 0 EQ,780,127
	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		8			0	0	00,668,16 22,572,50 79,32	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 80,21 0 0 20,36 0 20,36 0 20,960,08	0 0 0 288,92	79,296,279	74,796,107	87,643,204 0 83,643,204	114,879,784 0 53,413	0 100,003,111 64,625 1,620 0 0 0 75,000 2,600 0 0 170,600 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	204'824'523 0 0 0 0 0 0 0	128,181,082 0 34,281	136,736,829 90,806		27,515 27,515,412 307,613,412	0 (3,186) 306,964,065 326,006	0 387 658,125,253 680,663	0 0 09(333,002 723,546	0 784,825,269 1,275,696	0 0 672,929,681 991,967	0 68,013,68 1,396,718	0 769,367,885 1,075,663	0 0 007,588,000 603,672	8	0 0	0	0	0	0	0 0			0 0	0 22,512,686 0 806,832,860 0 4,986,802,827 0 7,996,662
	0 21,988,000 0 1,988,000 0 801,000	18,702 0 171,736 1 207,916	0 1,362,607 0 6,061,866 2,662,739	1,004,000 1,004,008 1,804,603	480,379 0 0,480,386 1,880,727	5,584,562 5,584,562 5,684,562	0 0 4,833,637 1,763,633 0	36,087,60 31,768,35	0 166 0 0 0 152,768,282 6 86,642,602	0 20,30 0 20,580,00 0 80,580,01	0 188,822 0 0 0 0 234,640 0 235,176,862 11 35,111,760	(3,800,800		26,679 76,178 0 0	0 114,791,781 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1,389 0 0 0	0 0 0 64,590		0	8	9	0 0	0	0 0	0	0	0			8	0 0	0	0	0	0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0	9	0 0 0	0 4,239,995 0 523,275 0 592,242,568 0 175,323,688
	0 0	0 0				0 0	0		0 0	0 0 0	0 0			1,881,667 0 67,636 0	1,3% 84,00 0 10,20,01	2,666 0 0	0	0		0 0 1,885	254,962,879	0 0 140,221,680 0	110,183,283	130,601,089 0	0 0 176,669,106 0	204,504,778 0	0 0 142,882,820	0 0 362,306,666	71,171,409	8	0 0	0 0		0	0	0 0			0 0	0 7,862 0 617,014 0 1,274,318,613 0 14,134,618
	0 144,321,395 0 0 0 (7,609,462)	0 0	8	8	8	626,652 0 0	29,580,209 0 0	36,438,58 7,404,26	0 0 8 0 0 0	0	0 0	60,831	19,400	61,687 0 0	986,257 0 0	170,408	21 0 0	0				0 0					0 0	8			0	0 0	0	0	0	0 0	8	0 0 0	0 0	0 086,316 0 190,960,301 0 7,604,260 0 (7,800,60)
	0 0		8	0 0 0	0 0 0	0			0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 10	0 0 0 22,880	60,812,111	450,000 0 0 46,280,552	3,753,556 4,663,966 0 63,853,856 84,066,0	9,375,768 10,903,768 0 83,500,889	34,010,010 0 34,039 88,613,017	29,600,150 0 1,707,838 80,780,550	18,896,685 0 1,827,877 56,866,600	99,112,400 0 1,471,988 66,712,330 111,460 F	10,007,000 0 100,000 01,007,700	10,160 0 791,602 101,818,128 126,819 Mr	0 764,288 90,882,653 161,990,000	0 0 1,111,786 91,217,094 171,044,941	0 0 1,270,656 100,102,870 204,109,666 0	0 2,184,618 138,512,866 822,782,882	0 1,702,664 96,628,500 229,086,327	0 1,309,606 139,522,627 309,987,626	0 980,779 180,798,894 280,370,116	0 0 0 64,962,960 115,180,886	8	0	0	0 0		0	0 0 0 0 0 0	0	9	0 0	0 121,887,231 0 21,881,712 0 21,182,687 0 1,911,017,017
	0 0		9	9	9	0 0	0 0	,00	0 0	0 0	0 0 12 22,880 17 1,694,311 0 4,885,311 0 12,614,311 0 0	(2, MA), ASS (MA), GO (A), ASS (A), ASS	0 40,103 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	EX, 042, 202 0 33, 1006 104, 1007 70, 1078 0 0 0 0, 002 0, 002 0, 003 0, 003	0,574,768 10,102,768 0,102,768 125,900,809 100,900,700 0 0,000,700 4,900,700	0 34,030,673 24,835 86,451,857 191,587,873 0 0 24,557,873 0 1,051,250	0 20,000,100 1,700,888 80,780,360 180,000,110 0 22,280,678 0,687,700	0 11,504,600 0 1,127,677 50,344,000 0 24,223,808 0 24,338,627 807,706	0, 20, 11, 100 0, 1, 471, 568 66, 742, 166 120, 668, 166 0, 0 6, 200, 166 0, 0 20, 111, 188	0 10,807,040 0 100,800 0,402,700 0 0,012,207 0 0,007,111 0 20,803,000 97,000,000	0 51,960 0 795,662 204,828,108 0 0 5,202,669 0 0 5,202,669	0 794,188 90,882,463 181,193,506 0 0 1,261,830 0 0 0,009,870	1,111,786 91,317,084 171,816,961 0 0 129,841 0 81,626,880		0	0	0				0 0	0 0	0	0	0	0 0			0 0	40 Total
	0 0 0 714,196,821	1 107,612	1,000,000	7,672,629	1,003,000	. 5,015,211	138,740,038	8 180,000,0	0 0 0 0	0 0 192 234,425,4	0 0 0 3 177 303,834,01	5, 907,124 8 263,079,90	1,990,600 27 262,600,660	4,217,100 0 244,474,60	4,800,700 530,830,530	1,011,210 0 811,611,101	4,617,710 0 883,696,76	8 607,786,32	20,110,116 0 765,186,800	22,583,506 87,060,286 895,285,003	1,048,686,328	0,00,00 0 1,20,70,03	FREFEE 0	1,407,044,319	2,129,662,790	F41F19F042	1,792,894,907	1,966,657,008	munum 1	-										0 190,740,880 0 27,000,589 0 29,447,679,077
aivers	7																																							
																				Total Comp	utable																			
	A 01	1 02	. 03	04	05	06	07	0:	8 09	9 1	0 1	7,00,00	2 13	14	15	16 4(M),144	17	18	19 8,30,70	20	21 82,864,286	22	23	24 N(NC),016	25	26 12,612,619	27	28	29	30	31	32	33	34	35	5 36	37	38	39	40 Total
•	•					• •						0 7,261,00	n 42,744,619	6,318,677	erintre	16,000,000	10,000,00	s s(sec.)	81,201,710	extendent	KUMUM	19,16,76	101,002,008	94,942,054	199,200,100	92,612,619	115,174,868	10,007,000	20,627,880					•						0 1,817,840,988
																				Federal Si	hare																			
	A 01	1 02	. 03	04	05	06	07	7 01	8 09	9 1	0 1	1,00,00	2 13	2000,881	15 6,121,80 17,80 W	2,21,11	17 N, SK, SK, SK,	18	19	20 ((((()))	21 61,807,108	22 *0,107,800	23 70,000,001	24	25 MARTERIA	26 60,000,200	27 77,010,475	28	29	30	31	32	33	34	35	5 36	37	38	39	40 Total
				-								0 1,679,10	0 23,272,627	21,281,217	21,104,211	11,785,672	31,484,38	2 31,963,51	a 10,000,000	67407408	61,040,000	11,107,810	78,500,896	71,881,802	16,617,686	64,661,272	77,042,425	60,160,567	12,876,088				-							0 891,791,909

Summary of Expenditures by Waiver Year

Created On: Wednesday, February 1, 2023 8:08 PM

Page: 1 of 2

Waiver: 11W00351

MAP Waivers

Con		

																																											Total Less
Waiver Name	A	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	Total	Non-Adds
2825(i)-like Evaluations																																											7,662,318
HERS Waver LDC Timelines																																											
Betamer Payments		1.099.821			-																	-								-												1.099.821	3.000.323
Total		18,792,395																											4,792,479	4,681,717												27,812,617	27,982,627

eder		

																																										Tota
Α	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	Total	Non
0	2,653,683	0	0																																							
0	6,667,975	0																																								
_	_A	A 01 0 2,612,615 0 6,817,915 0 1,863,312	0 2,653,683 0 0 6,667,695 0	0 2,618,688 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,610,665 0 0 0 0 0 6,667,955 0 0 0 0	0 2,600,600 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,685,685 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,652,655 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,685,685 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	O 2,601,600 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,661,665 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,665,665 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2002000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,55,545 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,845,84 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 238431 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 100 100 100 100 100 100 100 100 100 1	0 LANSES 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 JAMANE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 20020 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2,245,45 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 1.04.01 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 124341 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 120431	0 1AMB 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 144411 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		1 ANALY 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0 18820 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2 ABAN	2 (2444) 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	2 AMANU	1 20000 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 (AMAN) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 (A49)	1 (ANSIE) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 (A)(1) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 (A1991) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1.0400 1 1 1.0400 1 1.0400 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 (ASS) 1 (ASS	1 (AM) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	A 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Total control of the control of th